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ABSTRACT 
Cardiac remodelling, the reorganization of the heart which occurs in response 
to factors impacting its function, includes remodelling of the extracellular matrix 
(ECM) and hypertrophic cardiomyocyte growth. Pressure overload (PO) induced 
remodelling of the ECM is initially considered a compensatory mechanism to 
maintain myocardial integrity, but is also considered a progressive, negative event 
increasing myocardial stiffness. Adiponectin, an adipokine inversely correlated with 
type 2 diabetes and obesity, plays an important role in the adaptive response of the 
heart in various cardiomyopathies, however, adiponectin signalling leading to ECM 
regulation remains unclear. The studies presented here investigate the role of 
adiponectin in regulating cardiac remodelling with a particular focus on the ECM 
from a physiological and mechanistic perspective. 
Studies using wild-type (WT) and adiponectin deficient (AdKO) mice showed 
that PO induced left ventricular (LV) cardiac remodelling is delayed by adiponectin 
deficiency. The appearance of thick collagen fibres and activation of pro-fibrotic genes 
(MMPs and TIMPs) is delayed in AdKO mice subjected to PO when compared to WT 
mice. Cardiac hypertrophy and dysfunction, measured by echocardiography, is 
similarly delayed in AdKO mice. Furthermore, MEF2 activation determined using 
MEF2-lacZ reporter mice, is decreased in AdKO mice compared to WT mice following 
PO. 
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Studies in primary neonatal cardiac fibroblasts identified the APPL1-AMPK 
signalling axis as the mediator of adiponectin stimulated ECM remodelling through 
membrane localization of APPL1 and subsequent phosphorylation of AMPK, leading 
to MT1-MMP re-localization, MMP2 activation, and fibroblast migration. Also, 
adiponectin pre-treatment inhibited angiotensin II induced fibroblast to 
myofibroblast differentiation. Furthermore, in primary neonatal cardiomyocytes we 
identify the hypertrophic regulators Myocyte Enhancing Factor-2 (MEF2) and Atrial 
Natriuretic Factor (ANF) as downstream targets of adiponectin signalling.  
Lastly, using an in vivo model of reverse remodeling, we show that myocardial 
strain and cardiac hypertrophy are regressed following LV unloading. However, 
regression of cardiac fibrosis was incomplete leading to persistent small fibre fibrosis. 
Together these studies establish adiponectin as an important regulator of 
cardiac remodelling via the APPL1-AMPK signalling axis and MEF2 activation. 
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1.1 Diabetes and Cardiovascular Disease 
1.1.1 Prevalence and Impact of Diabetes in Canada 
Diabetes is a major chronic disease in both Canada and the United States, as 
2.4 million Canadians [1] and 25 million Americans [2] currently live with the disease, 
accounting for 6.8% of the Canadian, and 8% of the American population in 2013. 
Alarmingly, approximately 5.0 million Canadians and nearly 70 million Americans 
are currently classified as pre-diabetic (having a >30% chance of developing diabetes 
over their lifetime), and this number is commonly predicted to rise significantly. The 
impact of the rise of diabetes on our health care system is significant. The most recent 
available data estimates the total cost of diabetes in the year 2000 was $2.5 billion 
dollars [1]. When including costs associated with long-term complications 
(cardiovascular disease, kidney and eye disease, neurological disorders), it is 
estimated that the cost of diabetes increases 3.6 fold. Indeed, in addition to the 
increased prevalence of diabetes with age, the treatment and management of diabetic 
co-morbidities such as cardiovascular disease (CVD) represents the major leading 
expenditure for diabetic care.  
1.1.2 Types of Diabetes and the Metabolic Syndrome 
The group of metabolic pathologies termed diabetes encompasses a family of 
diseases of which diabetes mellitus is the most common and widely studied sub-group. 
Diabetes mellitus is characterized by high circulating levels of blood glucose leading 
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to polydipsia (increased thirst), polyuria (excessive urination) and glucosuria (glucose 
excretion through the urine), while by contrast diabetes insipidusis caused by kidney 
dysfunction or a deficiency in anti-diuretic hormone resulting in excessive urination 
without glucosuria or insulin resistance [3]. Diabetes mellitus is divided into 4 
subgroups: Type 1 Diabetes, also termed juvenile diabetes or insulin-dependent 
diabetes mellitus; Type 2 Diabetes, also referred to as adult-onset diabetes, or non-
insulin dependent diabetes mellitus (NIDDM); gestational diabetes, a variant which 
occurs during pregnancy, and may precede the development of NIDMM; other rare 
forms of hyperglycemia due to genetic defects in insulin secretion, treatment with 
high doses of glucocorticoids, or disorders such as cystic fibrosis. 
Type 2 diabetes (T2D) is the most common form of the disease, responsible for 
approximately 90% of the diabetic population worldwide, largely due to the obesity 
epidemic. The number of obese individuals around the world is growing at a 
staggering rate [4-7], and the population of Canada is not exempt: by 2007 it was 
estimated that 32% of Canadian adults were considered overweight, with 16% 
considered obese having a BMI ≥ 30 [8]. With the number of obese individuals on the 
rise globally, an alarming number of clinical studies have suggested a causal 
relationship between obesity and cardiovascular disease [9-12] in both men and 
women [13]. Given the close connection between obesity, insulin resistance, and heart 
function [14, 15] the term ‘The Metabolic Syndrome’ (and the related cardiometabolic 
syndrome), was coined to define the constellation of risk factors which greatly increase 
- 4 - 
 
the risk of T2D and CVD (table 1). The link between T2D and CVD, outlined by the 
now foundational Framingham study, is well accepted: diabetic patients have a 2 to 
4 fold higher chance of developing heart disease, while nearly 70% of diabetes related 
deaths are due to CVD. As such, diagnosis of individuals with the metabolic syndrome 
accounts for approximately 15% of Canadians [1], and as many as 23% of Americans 
[16].First described by Rubler et al in 1972, myocardial dysfunction in patients with 
diabetes (in the absence of coronary artery disease, hypertension, or valvular heart 
disease) has been termed diabetic cardiomyopathy (DBCM) and has gained attention 
as a major non-ischemic heart disease [17]. 
Table 1.1: Parameters of the metabolic syndrome. 
The metabolic syndrome may be diagnosed when 3 or more of the following are present. 
Adapted from [1] 
Elevated Waist Circumference ≥102 cm in males; ≥88 cm in females 
Reduced high-density lipoprotein (HDL) 
cholesterol 
<1.0 mmol/L in males; <1.3 mmol/L in 
females 
Elevated triglycerides ≥1.7 mmol/L 
Elevated blood pressure systolic ≥130 mmHg and/or diastolic ≥85 
mmHg 
Elevated fasting plasma glucose ≥5.6 mmol/L 
 
1.1.3 Diabetic Cardiomyopathy 
The hyperglycaemic (HG), hyperinsulinemic (HI), and dyslipidemic 
environment in T2D has direct and severe effects on cardiac function and structure 
(figure 1.1). The association between HI and cardiac hypertrophy was the subject of 
early clinical studies [18, 19] and is now well established, perhaps due to the cross-
talk between insulin signalling and growth. Indeed, insulin signalling has been 
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implicated in both physiological (PI3K/PKB/Akt/mTOR) and pathological (ERK, PKC, 
calcineurin) hypertrophy [20, 21], as well as activation of the FoxO (forkhead box 
proteins O) family of transcription factors. In fact, FoxO proteins are now established 
as critical regulators of insulin sensitivity, glucose metabolism, and cardiac 
hypertrophy [22], where high fat diet induced hyperinsulinemia and cardiac 
hypertrophy are associated with chronic FoxO activation leading to heart failure [23]. 
Increased circulating levels of fatty acids (FA) is a persistent finding in T2DM and 
DBCM patients, and is associated with impaired cardiomyocyte metabolism as 
myocyte FA uptake and oxidation fail to counter balance increased adipocyte lipolysis 
and hepatocyte lipid synthesis, leading to oxidative stress [15]. Stressed oxidative 
capacity and lipid accumulation lead to ceramide production and ROS generation in 
parallel with IRS-1 (insulin receptor substrate) serine phosphorylation, resulting in 
insulin resistance [24]. The normal heart derives 70% of its performance energy from 
the oxidation of fatty acids. Hemodynamic stress is known to induce a switch in 
energy substrate to glucose [25], although hyperglycaemia is less efficiently handled 
by mitochondria in the heart, resulting in higher ROS production, activation of poly 
(ADP-ribose) polymerase-1 (PARP-1), and the apoptosis cascade [24].  PARP-1 activity 
itself suppresses GAPDH activity, leading to multiple pathways resulting in cellular 
damage: advanced glycation end product (AGE) accumulation, the polyol pathway, 
protein kinase C activation, and overactivity of the hexosamine pathway [26]. AGE 
accumulation in the myocardium is closely associated with collagen cross-linking, and 
HG induced oxidative stress also leads to increased collagen deposition [27, 
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28],myocardial fibrosis [29], and diastolic stiffness through ERK1/2 signalling [30, 
31]. 
Angiotensin II, a strong marker of cardiac dysfunction and member of the 
renin-angiotensin-aldosterone system (RAAS) signalling pathway, is closely 
associated with many features of diabetic cardiomyopathy [15]. Angiotensin receptor 
density is increased in the diabetic heart [32] and was shown to induce insulin 
resistance, and stimulate the switch in cardiac substrate utilization through 
increased PDK expression [33]. Importantly, activation of the local RAAS in DBCM 
may induce oxidative damage, cardiomyocyte apoptosis, and cardiac fibrosis [34]. 
However, cardiomyocyte derived IGF-I can downregulate local AngII expression and 
cardiomyocyte apoptosis [15]. Therapeutically, AngII stimulated cardiac hypertrophy 
and fibrosis is attenuated by pioglitazone, a PPARγ targeting anti-diabetic therapy 
that has been extensively used in DBCM patients [35]. 
The toxic diabetic milieu of dyslipidemia, HG, and HI leading to cardiac 
hypertrophy, metabolic disturbance, apoptosis, and cardiac fibrosis, present clinically 
as cardiac dysfunction, and ultimately lead to heart failure. Within this complex 
environment, the dysregulation of numerous circulating factors such as the cardio-
important adipokine adiponectin plays an important role in the etymology of DBCM. 




Figure 1.1: Progression of hyperinsulinemia, dyslipidemia, and hyperglycemia leading to 
diabetic cardiomyopathy. 
Adapted from [36]. Cardiac fibrosis and hypertrophy are central features of the diabetic 
heart. Diastolic dysfunction may be an important early screening metric for DBCM [37]. 
 
1.2 Adiponectin 
1.2.1 Regulation of expression and post translational modification 
Amongst the numerous adipose derived factors (adipokines), adiponectin has 
gained considerable interest with respect to DBCM due to its anti-diabetic and 
cardioprotective effects [38]. The concentration of adiponectin in circulation is 
relatively high in normal individuals (~2 to 17 ug/ml) [39-41], and has shown an 
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inverse relationship with the progression of obesity, type 2 diabetes, and the 
metabolic syndrome [42-44]. First identified by four independent groups [45-48], the 
adiponectin monomer is the 30 kDa protein product of the APM1 gene mapped to 
human chromosome 3q27, a diabetes-susceptible locus [49], under transcriptional 
regulation by peroxisome proliferator activated receptor γ (PPARγ), CCAAT/enhancer 
binding protein (C/EBP), sterol regulatory element-binding protein 1c (SREBP), E47, 
and Id3 protein, of which PPARγ is the best characterized. 
PPARs are ligand-activated transcription factors belonging to the nuclear 
family of receptors [50]. PPARγ activity significantly increases adiponectin levels in 
circulation, while PPARγ deletion reduces circulating adiponectin levels [51, 52], 
ablating adiponectin’s anti-diabetic and cardioprotective effects [53, 54]. Accordingly, 
the thiazolidinedione (TZD) class of drugs (e.g. rosiglitazone and pioglitazone) are 
commonly prescribed treatments for T2D as a means to enhance insulin sensitivity 
and lower blood glucose levels and they work at least in part via increasing 
adiponectin levels through PPARγ activation [55-57].  
C/EBPα belongs to the basic lucine zipper family which plays a role in 
adipogenesis, and has been shown to regulate adiponectin expression either alone or 
in conjunction with PPARγ [58]. SREBP overexpression upregulates adiponectin, but 
little is known of its role in DBCM, although SREBP-1c may play a role in 
adipogenesis and the cardiac parasympathetic response [59]. 
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The downregulation of adiponectin in obesity, T2D, and cardiovascular disease 
is largely attributed to the increased inflammatory state and corresponding 
upregulation of pro-inflammatory cytokines such as tumour necrosis factor-α (TNFα) 
although the transcription factors CREB and NFAT have been also identified as 
repressors of adiponectin gene expression [60]. cAMP response element binding 
protein, CREB, which contributes to hyperglycaemia and insulin resistance through 
the regulation of glucose homeostasis, inhibits adiponectin transcription through 
upregulation of ATF3, a transcriptional repressor. Adipose tissue specific 
overexpression of a dominant-negative CREB increases adiponectin levels 
independent of resistin, TNFα, and IL-1β [60, 61].  
NFAT (nuclear factor of activated T-cells) are a family of transcription factor 
proteins found in adipose tissue that are upregulated in obesity and T2D. Deletion or 
overexpression of the NFAT binding site in the mouse adiponectin promoter has an 
inverse effect on promoter activity [62]. 
TNFα, an acute-phase pro-inflammatory cytokine responsible for the 
regulation of immune cell function, is commonly cited as a down regulator of 
adiponectin expression. TNFα suppresses gene expression of numerous upstream 
adiponectin expression activators including PPARγ, C/EBP, and SREBP [60], as well 
as inhibiting SP-1 promoter binding [63], thus decreasing adiponectin expression. 
TNFα may also acutely suppress adiponectin expression through PPARγ 
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phosphorylation, leading to decreased PPARγ binding activity, via JNK/PKC 
signalling [60]. 
The physiological effects of adiponectin may also be regulated post-
translationally. Structurally, the highly conserved 244-amino-acid adiponectin 
monomer belongs to a soluble collagen defense superfamily, including collagens type 
VII and X, and complement factor C1q [46], and is composed of a signal peptide, a 
variable N-terminal domain, a collagen-like domain and a globular domain at the C-
terminus [64]. The adiponectin protein must undergo post-translational modification 
before secretion: four conserved proline residues are hydroxylated and five lysine 
residues are hydroxylated then glycosylated before further processing to form 
adiponectin multimers [65]. Adiponectin oligomerization is now considered a critical 
step in the adiponectin production pathway, resulting in three adiponectin isoforms 
each of which exert independent responses in various target tissues: Trimer (low-
molecular-weight form: LMW; ~90 kDa), hexamer (medium-molecular-weight form: 
MMW; ~180 kDa), and oligomer (high-molecular-weight form: HMW; > 250 kDa) [66-
68]. These are collectively referred to as full-length adiponectin (fAd). The assembly 
of MMW and HMW adiponectin requires the formation of a cystine-cystine disulfide 
bond in the highly variable N-terminal region [68]. Adiponectin multimerization is 
regulated by the ER chaperone protein Ero1-Lα, protein disulfide bond isomerise 
(PDI) [69], and disulfide bond A oxidoreductase – like protein (DsbA-L) [70-73]. 
Expression of another chaperone protein Erp44, responsible for thiol-mediated 
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intracellular retention of adiponectin, has shown an inverse relationship with HMW 
secretion [74, 75]. In addition to directly stimulating adiponectin expression, PPARγ 
regulation of the adiponectin oligomer ratio may be due to selective upregulation of 
Ero1-Lα and downregulation Erp44 [69, 71, 76]. 
Recent studies have proposed the importance of assessing high-to-low 
molecular weight isoform ratios when correlating adiponectin levels with clinical 
parameters assessing the metabolic syndrome [77, 78]. Accordingly, adipocyte 
conditioned media from STZ-induced diabetic rats mediates different metabolic 
effects in cardiac and skeletal muscle, and this correlates with changes in 
concentrations of oligomeric adiponectin forms, when compared with wild-type 
controls [79]. Furthermore, fAd may be cleaved by leukocyte elastase to liberate the 
globular C-terminal fragment (gAd) [68, 80] and exert direct cellular effects [81, 82].  
1.2.2 Local production of adiponectin 
Evidence of local expression has expanded the view of adiponectin from its 
classic role as an adipokine with wide ranging endocrine effects to a new concept in 
which the secretion of adiponectin from target tissues may off-set impaired 
bioavailability of circulating adiponectin. This may be especially important in tissues 
susceptible to pro-fibrotic processes in disease states such as the heart.   
Adiponectin expression in the heart was first confirmed in isolated 
cardiomyocytes [83], and was subsequently found to be upregulated in the post-
- 12 - 
 
ischemic murine heart [84], to attenuate cardiomyocyte hypertrophy in vitro [85], and 
to play a role in a porcine model of dilated cardiomyopathy [86]. Accordingly, the 
adiponectin transcription factor PPARγ has been shown to inhibit cardiac 
hypertrophy and attenuate AngII-induced cardiac fibrosis [35, 87]. The clinical 
relevance of heart derived adiponectin has yet to be fully elucidated but the local 
adiponectin system was found to be dysregulated in patients with dilated 
cardiomyopathy [88]. 
Skeletal muscle has been shown to produce adiponectin with the same relative 
multimeric composition to adipose derived adiponectin [55, 89]. Rosiglitazone, 
another TZD and PPARγ agonist, increases adiponectin mRNA transcription, as well 
as translation of intracellular and secreted protein from L6 skeletal muscle cells, 
which  was shown to exert functional metabolic effects including enhanced insulin-
stimulated Akt phosphorylation and glucose uptake [55]. Accordingly, PPARγ-
mediated skeletal muscle adiponectin production mediates autocrine effects to 
improve insulin sensitivity and could protect against high-fat diet-induced insulin 
resistance in vivo [85]. It has been suggested that skeletal muscle adiponectin content 
increases in response to certain inflammatory conditions and obesity in an attempt at 
providing local anti-inflammatory and antioxidative protection [90-92]. Indeed the 
globular form of adiponectin mediates potent metabolic effects in skeletal muscle and 
it is conceivable that elevated local amounts of gAd are produced in inflamed tissue 
by elastase enzyme derived from infiltrating inflammatory cells. Finally, autocrine 
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effects of gAd have recently been identified in the regulation of skeletal muscle cell 
differentiation [93, 94]. 
Adiponectin was also shown to be produced by the liver in response to carbon 
tetrachloride induced hepatofibrosis [95], in osteoblasts [96, 97], in the pulmonary 
vascular endothelium [98, 99], and in the pituitary [100, 101]. 
1.2.3 Adiponectin signalling 
Intracellular adiponectin signalling is mediated through the binding of 
adiponectin with the transmembrane adiponectin receptor isoforms AdipoR1 and 
AdipoR2 [102] and also T-cadherin [103] which has been shown to mediate 
adiponectin stimulated cardioprotective effects [104] (figure 1.2). AdipoR1 and 
AdipoR2 have seven transmembrane domains with an intracellular N-terminus and 
an extracellular C-terminus, and are thought to function in a tyrosine 
phosphorylation independent manner [54], while less is known about the signalling 
mechanisms mediated by T-cadherin. AdipoR1 has highest binding affinity for gAd 
and is the major form found in cardiomyocytes and skeletal muscle [82] whereas 
AdipoR2 is most highly expressed in liver [105]. 
APPL1 (Adaptor protein containing PH domain, PTB domain and Leucine 
zipper motif) is an adaptor protein identified by Mao et al. [54] that interacts with the 
N-terminal intracellular domain of both AdipoR1 and AdipoR2 through its PTB 
domain. APPL1 is now regarded as a critical mediator of adiponectin signalling and 
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as a regulator of the crosstalk between the adiponectin and insulin signalling 
pathways [67]. APPL1 has been shown to interact with the p110α catalytic and p85 
regulatory subunits of PI3K [106], and Akt [107]. APPL1 was found to be a critical 
mediator of adiponectin stimulated cardiac fibroblast regulation of the ECM [108]. 
Indeed, adiponectin was found to stimulate APPL1 translocation towards to the cell 
membrane [108] where it can interact with AdipoRs to mediate downstream 
signalling and metabolic events [54]. Other more recently identified adaptor proteins 
which have been suggested to be involved in adiponectin’s intracellular signal 
transduction include activated protein kinase C1 (RACK1; [109]), ER protein 46 
(ERp46; [110]), and protein kinase CK2β [111]. Among the adaptor proteins, only 
APPL1 associates with both AdipoR1 and AdipoR2 while RACK1, ERp46, and CK2β 
bind to AdipoR1. It has now been shown that APPL1 plays an important role in 
mediating adiponectin’s metabolic effects in liver, muscle, and endothelial cells [112] 
as well as its cardioprotective effects [113, 114]. RNAi-mediated RACK1 knockdown 
prevented adiponectin regulated glucose uptake in HepG2 cells [109]. 
Pharmacological inhibition of CK2β attenuated adiponectin signalling in skeletal 
muscle cells [111]. Co-immunoprecipitation also confirmed the interaction between 
ERp46 and AdipoR1, but not AdipoR2, and interestingly the suppression of ERp46 
expression resulted in increased cell surface AdipoR1 levels and enhanced 
adiponectin stimulated phosphorylation of AMP kinase (AMPK) but reduced 
phosphorylation of p38-mitogen-activated protein kinase (MAPK; [110]). 
- 15 - 
 
Although APPL1 shows nuclear localization following adiponectin treatment 
[67], APPL1 does not have a nuclear localization sequence (NLS). APPL1 localizes 
with early endosomes, and can undergo nucleo-cytoplasmic shuttling to regulate 
transcriptional pathways via HDAC interactions [115]. In fact, in addition to 
adiponectin signalling, APPL1 is currently known to interact with proteins involved 
in a variety of pathways including insulin, Wnt, and NF-κB signalling [67, 115].  
The ability of adiponectin to counteract deterioration in cardiac function is 
mediated by metabolic, anti-apoptotic, anti-fibrotic, and anti-hypertrophic effects 
[114, 116-120]. Adiponectin has been shown to regulate fatty acid β-oxidation in the 
heart. In cell based in vitro studies of isolated cardiomyocytes, adiponectin was shown 
to stimulate the phosphorylation of AMPK, IRS1, and Akt (T308 and S473) 
correlating with the regulation of glucose and fatty acid uptake and metabolism [121], 
and to target cofilin to mediate remodelling of the actin cytoskeleton leading to the 
translocation of lipoprotein lipase (LPL) to the cell surface [122]. Adiponectin was also 
shown to stimulate the phosphorylation of acetyl coenzyme A carboxylase (ACC), as 
well as to induce CPT-1 expression and activation through AMPK [123]. Recently 
[113], we demonstrated that adiponectin increases fatty acid uptake, CD36 
translocation, and insulin-stimulated glucose transport as well as Akt 
phosphorylation in isolated adult cardiomyocytes, and enhances fatty acid oxidation 
in conjunction with AMPK and ACC phosphorylation in the isolated working heart. 
However, despite an increase in fatty acid oxidation and myocardial oxygen 
- 16 - 
 
consumption, adiponectin increased hydraulic work, and maintained cardiac 
efficiency [113]. Similarly, enhanced adiponectin sensitivity through transgenic 
overexpression of APPL1 was shown to protect mice fed a high-fat diet from cardiac 
dysfunction [124]. 
The phosphorylation of AMPK was shown to attenuate norepinepherine 
induced cardiomyocyte hypertrophy and ERK phosphorylation [116], angiotensin II 
induced NF-κB activation and hypertrophy [125], and also shown to fully [118], or 
minimally [120] attenuate hypoxia–reoxygenation induced apoptosis. Adiponectin 
was shown to attenuate hypoxia–reoxygenation induced apoptosis in H9C2 cells 
through the AdipoR1/APPL1 signalling pathway [114]. Additionally, our recent study 
in isolated neonatal cardiac fibroblasts showed that adiponectin regulates 
remodelling of the ECM through activation of MMP2 and translocation of MT1-MMP 
via the APPL1-AMPK signalling axis [108]. 
 




Figure 1.2: Adiponectin Signalling. 
AdipoR1 and AdipoR2 are transmembrane adiponectin receptors that bind the adaptor 
protein APPL1 through the PTB domain and have been shown to mediate many of 
adiponectin’s effects. T-cadherin lacks an intracellular domain but may be essential for 
adiponectin’s effects in the heart. 
 
1.3 Adiponectin and cardiovascular disease 
With the growing appreciation of adipose tissue as a dynamic endocrine source 
of a comprehensive bioregulatory secretome (termed adipokines) [126, 127], and the 
close association between obesity, the metabolic syndrome, and CVD (section 1.1) 
there has been great interest in the direct myocardial effects of the adipose derived 
insulin-sensitizer adiponectin, which is now closely associated with CVD [38, 112, 
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128-133]. The in vivo study of adiponectin in the heart largely relies upon surgical 
intervention (coronary artery ligation: MI, transverse aortic banding: POH) or 
administration of inducers of cardiac dysfunction (e.g. Angiotensin II), in various 
mouse backgrounds. Sections 1.3.2 and 1.3.3. will discuss in vivo findings regarding 
adiponectin and CVD with specific emphasis on POH and AngII infusion as two well 
established in vivo models of non-ischemic cardiomyopathy. 
1.3.1 Human studies 
High expression from visceral adipose tissue was initially considered an important 
factor in the potential impact adiponectin might have in the pathogenesis of diseases 
associated with obesity such as CVD [134]. This was later supported with data 
proposing adiponectin as a regulator of endothelial adhesion molecules, while 
adiponectin protein was detected in ruptured vascular walls [135, 136]. Indeed, 
circulating levels of adiponectin showed an inverse relationship with coronary artery 
disease, acute myocardial infarction, and essential (idiopathic) hypertension, [137-
140]. 
While there is speculation that adiponectin may serve as an independent risk 
factor for the development of CVD [141-143], the high molecular weight isoform of 
adiponectin is now considered a more accurate independent predictor of heart failure 
outcome [144, 145]. Pioglitazone, a known PPARγ agonist and insulin sensitizing 
therapeutic, increases circulating adiponectin levels, and was shown to decrease 
inflammation and atherogenesis independent of glycemic control in patients with 
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CVD, suggesting that adiponectin’s influence was independent of its role as an insuin 
sensitizer [146, 147]. 
The volume of data examining the link between adiponectin and CVD is 
growing rapidly and there is increasing discord in the conclusions made in each study 
[132, 148]. For example, high circulating levels of adiponectin were associated with a 
low risk of MI in men aged 40 to 75 without signs of cardiovascular disease [149], and 
a 10 year follow up study in 70 year old men showed that serum adiponectin was 
associated with a lower risk of coronary heart disease, independent of BMI and 
glycemic control [150]. However, in the Jackson Study comprising a broad metabolic 
spectrum of the black community, adiponectin was found to correlate with LV mass 
in patients with hypertension and insulin resistance [151]. Accordingly, increased 
circulating adiponectin levels were associated with LV diastolic dysfunction in 
patients with hypertrophic cardiomyopathy [152], and was identified as a risk factor 
for coronary heart disease in elderly men [153]. Conversely, another study of the 
elderly population instead showed that higher adiponectin concentrations predicted 
reduced risk of non-fatal MI [154].  
In an effort to clarify and summarize what is known about adiponectin in heart 
disease, two very thorough reviews of current clinical literature conclude there is no 
clear association between adiponectin and CVD [38, 133]. Clearly, the multifaceted 
etymology of cardiovascular disease and the complex regulation of adiponectin and its 
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isoforms in obesity, T2D and inflammatory conditions may be obscuring these results 
making definitive conclusions of observational data elusive.  
1.3.2 Animal studies 
Adiponectin knockout (AdKO) mice exhibit a normal cardiac phenotype when 
unstimulated: interstitial fibrosis, cardiomyocyte cross-sectional area, and 
echocardiographic assessment of cardiac function are similar between AdKO and 
wild-type (WT) mice. Transverse aortic banding (MTAB), a mouse surgical model 
commonly used to simulate clinical pressure overload of the left ventricle, is known 
to induce an increase in LV mass, increased fibrosis, and expanded myocyte cross-
sectional area in WT mice [155]. Following MTAB surgery, AdKO mice exhibit signs 
of exacerbated LV hypertrophy, increased interstitial fibrosis, and increased LV 
posterior wall thickness, a common measure of hypertrophic cardiac remodelling, all 
of which are ameliorated upon adenoviral-adiponectin administration [116]. 
Accordingly, PPARγ heterozygous, and db/db mice also show an exaggerated 
hypertrophic response to MTAB, suggesting that adiponectin deficiency, common in 
T2D and obesity, exacerbates PO induced cardiac dysfunction [116, 156]. While the 
exact mechanisms precipitation cardiac dysfunction in AdKO mice are not clear, 
impaired AMPK signalling, glucose metabolism and subsequent disruption of 
adiponectin mediated angiogenesis  are noted in adiponectin deficient mice following 
MTAB [157, 158].  
- 21 - 
 
Adiponectin has also been shown to be protective against myocardial infarction 
[118]. Interestingly, despite a significant reduction in adiponectin levels (~50%) 
following MI [119] or MTAB [159], Adiponectin was shown to localize to the infarct 
scar both in wild-type mice and in patients following ischemic injury, through leakage 
from the vascular compartment [160]. Indeed, myocardial accumulation of 
adiponectin, through association with collagen [117], is a putative mechanism 
through which adiponectin could induce cardioprotective signalling in a 
hypoadiponectinemic environment. Accordingly, a local adiponectin system has been 
shown in patients with dilated cardiomyopathy which is regulated independently of 
the endocrine adiponectin system [88]. 
However, recent studies in adiponectin deficient mice using MTAB to induce 
pressure overload have yielded some conflicting data. The study published by Liao et 
al in 2005 clearly shows the predicted progressive decline in cardiac function following 
MTAB in WT mice, and the exacerbated decrease in ejection fraction (EF) and 
fractional shortening (FS) in AdKO mice beginning at 2 weeks following surgery [157]. 
Similarly, a study published comparing WT, AdKO, and T-cadherin KO mice, showed 
the decrease in FS and increase in heart weight-to-body weight ratio in both AdKO 
and T-cadherin KO mice compared to WT mice after 4 weeks of PO [104]. By contrast, 
two papers published in 2010 by the Stanley group show an increase in posterior wall 
thickness in AdKO mice in response to MTAB, but no change in other functional 
parameters (end diastolic volume, end systolic volume, ejection fraction) [161, 162]. A 
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follow-up study published by the same group in 2011 similarly failed to show an effect 
of MTAB on cardiac function in AdKO mice, and also showed that high-fat diet 
accelerated cardiac decline in WT but not AdKO mice [163]. They conclude that 
adiponectin does not confer cardiac protection in the overloaded myocardium, 
adiponectin deficiency may be protective against the development of cardiac 
dysfunction, and that adiponectin may play a permissive (detrimental) role in the 
progression of cardiac remodelling. Indeed, a finer analysis of the study published by 
the Walsh group in nature medicine, the first comprehensive comparison of WT and 
AdKO mice following MTAB, posits an alternative interpretation. After 1 week of PO, 
WT mice show a significant decrease in fractional shortening compared to AdKO mice 
despite indications of hypertrophic remodelling (increased heart weight-to-body 
weight ratio and LV posterior wall thickness) in both groups [116]. Decreased 
fractional shortening with increased LV posterior wall thickness is a negative 
indicator of cardiac function, which suggests that the WT mice from this study are in 
progressive heart failure while the AdKO mice remain in the compensated phase of 
cardiac remodelling [164, 165]. 
Currently, similar to clinical findings, the conclusions from detailed focused 
studies linking adiponectin action to cardiac dysfunction in mice are mixed. Certainly, 
compensatory upregulation of cardioprotective agents in whole body and germ line 
adiponectin knockout models need to be considered as possible confounding factors. 
While these considerations may lead to the discovery of new therapeutic targets, more 
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sophisticated approaches such as inducible or cardiac specific adiponectin deficient 
mouse models, as well as models targeting downstream adiponectin signalling 
(AdipoR1/2, APPL1/2), will help to further elucidate the role of adiponectin in heart 
disease. 
1.3.3 Adiponectin and Angiotensin II 
AngII, the pluripotent member of RAAS known to play a central role in the 
homeostatic regulation of the cardiovascular system [166], is known to exert 
hypertrophic and apoptotic effects on cardiomyocytes, and is a major therapeutic 
target [167]. RAAS is upregulated in obesity and CVD, and shows an inverse 
relationship with adiponectin [168]. Therapeutic inhibition of RAAS was shown to 
lead to increased adiponectin levels in circulation in patients with essential 
hypertension [169]. 
AngII infusion is a common in vivo methodology mimicking the pathology of 
dilated cardiomyopathy [170-173]. AngII potently targets cardiac fibroblasts to 
increase collagen production [174] leading to severe cardiac fibrosis and dysfunction. 
Owing to the hypoadiponectinemic-hypertensive environment in DBCM patients, 
numerous groups have studied AngII infusion in AdKO mice. AngII induces fibrosis 
(increased Col I and Col III), MMP2 and MMP9 activities, TGFβ expression, and 
cardiac dysfunction, and these are consistently exacerbated by adiponectin deficiency 
[159, 175]. Administration of adiponectin or piogitazone treatment attenuates these 
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effects [35, 116]. Accordingly, adiponectin cardioprotection is blocked in PPAR-α-KO 
mice treated with AngII [176]. 
There is growing evidence of systemic and intracellular negative cross-talk 
between AngII and adiponectin signalling (figure 1.3). Adiponectin inhibits AngII 
induced oxidative stress in renal tubular cells, vascular smooth muscle cells, and 
cardiomyocytes [177-179]. AngII was also shown to induce hypoadiponectinaemia 
[180, 181] and adiponectin resistance [182], while, interestingly, AngII type 1 receptor 
agonists have been shown to activate PPARγ [183, 184]. 
PARP-1 has been shown to regulate adiponectin gene expression through 
poly(ADP-ribosyl)ation of PPARγ. Knockdown of PARP-1 increases PPARγ binding 
activity, and the expression of both adiponectin and adiponectin receptor 1 (AdipoR1) 
[185]. Importantly, PARP-1 activity is increased through various mechanisms in 
diabetes including hyperglycemia (section 1.1.3), and through AngII activity. 
Regulation of adiponectin expression by hyperglycemia [24] and Angiotensin II [186] 
through PARP-1 may be an important mechanism in DBCM. 
The reciprocal relationship between AngII and adiponectin in the heart may 
be of great significance especially considering the discovery of the local RAAS, and 
the emerging recognition of a local adiponectin system within the heart. 




Figure 1.3: Inhibitory cross-talk between adiponectin and AngII signalling. 
Adiponectin inhibits AngII induced hypertrophy via NF-κB and ERK signalling. AngII 
attenuates adiponectin expression via poly(ADP-ribosyl)ation of PPARγ via PARP-1 
activation. Adiponectin upregulation of MEF2 activity may be through phosphorylation of 
p38 (dotted line). 
 
 
1.4 Cardiac Remodelling in Cardiovascular Disease 
Cardiac remodelling is the generalized term used to define reorganization of 
the heart in response to factors that impact the homeostasis of its function. Dynamic 
changes in the myocardium including gene expression, molecular, cellular and/or 
structural alterations are coordinated to adapt to various stressors (hemodynamic, 
pathological, idiopathic, etc…), or are dysregulated in the progression of heart disease 
leading to failure [14, 128, 187-192]. The heart is a heterogeneous organ composed of 
various tissues and cell types. Cardiomyocytes, providing contractile properties 
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within the heart, consume the majority of metabolic resources and account for 
approximately 70% of the myocardium by cell volume. Cardiac fibroblasts, primarily 
responsible for regulation of the extracellular matrix (ECM), are the most abundant 
cell type in the heart despite constituting a smaller volume than cardiomyocytes. 
Other cell types including vascular smooth muscle cells, endothelial cells and 
macrophages exert specialized and critical roles in the normal and remodelling heart.  
Left ventricular (LV) structure and contractile function are coupled in the 
progression from a normal state to failure.  LV structure is altered in non-ischemic 
heart disease in response to increased hemodynamic load as the heart adapts to 
maintain sufficient cardiac output to adequately supply blood to the body. The non-
diseased heart adapts to subtle changes in hemodynamics (e.g. vasoconstriction) 
according to the Frank-Starling law: LV stroke volume increases in response to 
increased end diastolic volume (increased LV pre-load). The LV wall is stretched to 
accommodate the increased end diastolic volume, resulting in increased length of the 
myocyte sarcomere, the structure where in contraction-relaxation coupling is defined 
[193]. Small-angle X-ray diffraction studies of contracting ventricular preparations 
recently determined that systolic contractile force is increased when sarcomere 
stretch induces a reorientation that reduces the search volume required by the myosin 
head to find a stereo-specific actin binding site [194].  These subtle changes are clearly 
adept in providing acute adaptations to normal variation in vascular dynamics. 
However, the hemodynamic stresses in heart disease supercede compensation by the 
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Frank-Starling law. Instead, the myocardium reacts at the transcriptional level, 
leading to an expansion of LV mass and remodelling of the myocardium. 
1.4.1 Mechanics of hypertrophy and clinical diagnosis 
Increased LV mass, termed LV hypertrophy (LVH), is commonly considered a 
principle adaptive remodelling event, and is manifest in two distinct stress-dependent 
patterns: pressure overload hypertrophy (POH) and volume overload hypertrophy 
(VOH). An elegant catheterization experiment performed in 1975 in patients with LV 
POH, LV VOH, or no evidence of heart disease, for the first time demonstrated the 
differential LV wall stresses of pressure overload (PO) and volume overload (VO) 
during the contractile cycle [195]. It was theorized based on LaPlace’s Law that 
distinct PO results in increased LV wall stress during contraction (systole) leading to 
concentric hypertrophy, whereas VO results in increased diastolic wall stress in the 
relaxed LV resulting in eccentric hypertrophy (figure 1.4). Structurally, concentric 
hypertrophy is characterized by the increase in LV wall thickness, reduction in LV 
volume, and increase in systolic contractile force as myofibrils are added in parallel 
to increase the coordinated stroke force. By contrast, in eccentric hypertrophy, LV 
wall thickness is decreased and volumetric capacity is increased as sarcomeres are 
added in series, reducing diastolic stress (figure 1.4) [196]. Many clinical studies in 
patients with PO (hypertension, ventricular outflow obstruction) and VO 
(aortic/mitral valve regurgitation) have supported these findings [197]. 
Echocardiography currently serves as the gold-standard by which to differentiate 
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these disparate geometric changes, and holds prognostic value in the prediction of 
patient outcome. 
     
Table 1.2: Echocardiography measures of cardiac performance 
Changes in measures of cardiac performance in pressure or volume overload. Cardiac 
function is decreased in the initial stages of pressure overload, but normalize following 
compensatory (comp) remodelling. 
Functional Measure Abbreviation 
Δ in PO 
(initial) 
Δ in PO 
(comp) 
Δ in VO 
Heart Rate HR - - - 
End Systolic Diameter ESD ↓ - ↑ 
End Diastolic Diameter EDD - - ↑ 
End Systolic Volume ESV ↓ - ↑ 
End Diastolic Volume EDV ↓ - ↑ 
Stroke Volume SV ↓ - ↑ 
Ejection Fraction EF ↓ - - 
Fractional Shortening FS - - - 
Cardiac Output CO ↓ - ↑ 
Left Ventricular Mass LV Mass - ↑↑↑ ↑ 
Posterior Wall Dimension in 
diastole 
LVPWd - ↑↑ ↓ 
 
Ultrasound echocardiography is a critical tool used by researchers and 
clinicians to study the structure and function of the heart in real time. Typical 
measurements of LV function are listed in table 1.2 and the following progressions of 
VO and PO are depicted in figure 1.4. Early VO: the LV undergoes a passive expansion 
of EDD and EDV through the Frank Starling mechanism, resulting in initially high 
diastolic filling pressures and symptoms of heart failure. Prolonged VO: ESD and ESV 
increase (eccentric hypertrophy), resulting in an increase in SV, but normalized EF. 
These remodelling events lead to normal LV pressures, a relative decrease in wall 
stress, and the abolition of patient symptoms. The prognosis for patients with chronic 
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VO is favourable, with a 75% survival rate after 5 years, and 50% survival up to 10 
years [198]. By contrast, in PO, initially compensated LV function decompensates 
over time leading to congestive heart failure (CHF). Early PO: Increasing LVPWd, a 
defining feature of compensatory concentric remodelling in response to PO, is 
accompanied by increased LV filling (diastolic) pressures. The LV can then exert 
greater contractile force to compensate for the increased wall stress. Compensatory 
POH: increased LVPWd and LV diastolic pressure lead to near-normal EDV, and 
normal indicators of cardiac function (EF, FS, and SV). In this phase, fibroblasts 
within the LV begin to expand the collagen ECM to provide support against the 
increased wall stress, and to provide an expanded contractile framework for the 
myocytes. Prolonged/decompensated PO: Excessive ECM expansion leads to LV 
stiffness which in turn begins to impair diastolic compliance (diastolic dysfunction), 
thereby reducing EDV and SV. To maintain SV, CO, and systolic pressure, diastolic 
pressures increase until pulmonary congestion occurs. Chronic PO leads to 
decompensation marked by reduced LV contractile function (due to apoptosis and 
necrosis), LV dilation, and severely impaired vascular dynamics leading to blood 
accumulation in peripheral tissues (congestive heart failure) [198]. 
Recently, an eight-year echocardiographic assessment study of LV geometry 
in 1020 hypertensive patients with either concentric or eccentric hypertrophy was 
published. Patients with concentric hypertrophy exhibited increased systolic and 
diastolic blood pressures, while patients with eccentric hypertrophy displayed 
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increased LV internal diameter. Furthermore, hearts with concentric and eccentric 
hypertrophy exhibited signs of cardiac dysfunction predicted by the remodelling 
patterns outlined above: hearts with eccentric hypertrophy showed decreased EF and 
FS, indices of systolic dysfunction, while hearts with concentric hypertrophy exhibited 
impaired LV isovolumetric relaxation time, and LV deceleration time, common 
features of LV fibrosis and diastolic dysfunction [199]. 
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Figure 1.4: Schematic of the progression of POH and VOH leading to HF 
The development of concentric hypertrophy in PO serves to decrease systolic wall stress, 
while increasing fibrosis decreases CO and induces diastolic dysfunction, leading to 
eccentric hypertrophy and failure. Adapted from [196, 200] 
 
While LV fibrosis is largely considered absent or downregulated in VOH [201], 
increased LV fibrosis is a hallmark of POH that holds significant prognostic value. A 
study of patients with aortic valve stenosis (a clinical model of PO) demonstrated an 
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increased risk of mortality in the group with a higher fibrosis index as calculated 
through endomyocardial biopsy. Specifically, fibrosis tissue mass index was positively 
correlated with end systolic wall stress, and ESD and EDD, and negatively correlated 
with FS, EF, and LVPWd, indicating a negative correlation between myocardial 
fibrosis and cardiac function. Strikingly, patients diagnosed with severe fibrosis (high 
fibrosis tissue mass index) had the lowest survival rate (<50%) compared to the group 
with a relatively mild fibrosis mass tissue index (90%) after the 10 year follow-up 
[202]. 
The hypertrophic remodelling patterns seen in PO and VO seek to normalize 
cardiac function through the Law of LaPlace [σ = (p ∗ r)/2t] which relates chamber 
wall stress (σ) to pressure within the cavity (p), chamber radius (r), and wall thickness 
(t). Accordingly, despite very different geometries and intraventricular pressures, 
VOH and POH result in initially normalized systolic stress patterns when compared 
to normal patients  [195]. 
1.4.2 Hypertrophic signalling and gene regulation 
In vivo studies have sought to delineate the distinct gene profiles induced in 
PO (aortic constriction) [203, 204]  and VO (aortocaval fistula) [201, 205-207]. Direct 
temporal comparison of PO and VO in rats showed similar progressive changes to 
heart weight-to-body weight ratio and ANF expression (a feature of the fetal gene 
program) following PO and VO, whereas skeletal α-actin, β-MHC, and SERCA2 
mRNA were increased following PO, and there was no detectable change in these 
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markers in VO compared to sham surgery. This suggests a difference in myocardial 
remodelling favouring increased contractility during PO in comparison to VO [208].  
A recent study utilizing a novel balloon technique to impose cardiac phase-
targeted LV load to the heart ex vivo, distinguished the molecular patterns elicited 
through the induction of systolic overload (SO; analogous to pressure overload) versus 
diastolic overload (DO; analogous to volume overload) [209]. Bioinformatics analysis 
revealed 140 and 77 distinct genes regulated in SO and DO respectively. 
Furthermore, SO activated proliferation and apoptosis gene profiles, and stimulated 
the activation of ERK, JNK, and CaMKIIsignalling. DO was associated with 
increased gene markers for fibrosis and connective tissue cells, as well as increased 
p38 signalling. ANP, a well-established marker of POH and VOH, was found in this 
study to be upregulated by only DO [209], although this may due to the cyclical-
temporal regulation of ANP in VOH[207]. 
Both POH and VOH are associated with activation of the fetal gene program, 
a protective reversion to the expression of genes involved in the growing heart, 
intended to slow the progression of heart disease [188, 210]. The fetal gene program 
is responsible for the change in expression of many genes (table 1.3); most notably:  
ATP-demanding α-myosin heavy chain (α-MHC) is replaced by the less demanding β-
myosin heavy chain (β-MHC) to conserve energetics; the preferred energy substrate 
is switched from oxidation towards glycolysis; and activation of the natriuretic factor 
family (NFF) is increased [197].  




However, there is evidence that the shift from α-MHC to β-MHC, as well as 
the reduced oxidative capacity, are maladaptive events leading to decompensated 
heart failure [211]. On the other hand, the NFF (ANP: atrial natriuretic peptide; BNP: 
brain natriuretic peptide; CNP: C-type peptide) exert well-characterized protective 
effects on the cardiovascular system: vasorelaxation, natriuresis (excretion of sodium 
in the urine leading to lower blood volume) and concomitant diuresis (increased 
excretion of urine), suppression of myocyte hypertrophy, and inhibition of the RAAS 
[212].  The NFF have also been shown to function through the cardiac fibroblasts to 
exert potent anti-fibrotic effects. BNP inhibited TGFβ stimulated migration and 
collagen I expression from isolated human cardiac fibroblasts, and also inhibited 
fibroblast proliferation and conversion to the hyper-secretory myofibroblast cell type 
[213]. Accordingly, BNP knockout mice exhibit an increased basal fibrotic phenotype 
which presents as multi-focal fibrotic lesions in the LV that increase in number and 
size in response to PO [214]. Although more recently characterized with respect to 
heart failure [215], CNP also exerts antifibrotic and antiproliferative effects in the 
myocardium [216]. NFF transcription is regulated by numerous well characterized 
factors involved in cardiac hypertrophy such as GATA4/5/6, NF-κB, and MEF2 (table 
1.3).  
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Table 1.3: Transcriptional regulation of the fetal gene program 
Gene Transcriptional Regulation 
ANP MEF2, GATA4/5/6, SRF, Tbx5, Nkx2.5, ZPF260 
BNP NF-AT, NRSF, NF-κB, SRF, TEF-1, XBP-1, GATA 4/5/6 
β-MHC Nkx2.5, MEF2C, GATA4/5/6 
Sk-αActin TEF, SRF, Sp1 
 
The myocyte enhancing factor-2 family of transcription factors (MEF2A, B, C, 
D), are well established as mediators of tissue development [217], and are also known 
to play a role in cardiac hypertrophy [211, 218-220]. MEF2 DNA binding sequences 
have been identified in the promoter regions of α-MHC [221], SERCA2 [222], skeletal 
α-actin (Skα-actin) [223], and also dystrophin, desmin, and some myosin light-chain 
isoforms [219]. MEF2 activity is upregulated by both PO and VO [221], while 
transgenic overexpression of MEF2A and MEF2C increases NFF and SK α-actin 
expression, facilitates a switch towards β-MHC, and decreases ventricular 
performance, indices of dilated cardiomyopathy  [218]. Transcriptional activity of 
MEF2 is regulated through MEF2-HDAC (repression) or MEF2-HAT (transcription) 
complex formation [211]. Phosphorylation of MEF2 by p38 or ERK also increases 
MEF2 transcriptional activity [224]. Although both p38 MAPK-MEF2 and ERK5-
MEF2 signalling cascades have been implicated as pro-hypertrophic [219], ERK and 
p38 MAPK may induce distinct hypertrophic pathways through phosphorylation of 
different target sequences on MEF2, and also targeting of different members of the 
MEF2 family [224]. 
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As detailed previously (chapter 1.1.3), insulin has been implicated in the 
pathogenesis of diabetic cardiomyopathy. However, streptozotocin induced diabetes 
(a common diabetic model lacking insulin) demonstrated the association of 
hypertrophic markers (AngII, MEF2, ANP and BNP) with high glucose and insulin 
deficiency [225, 226]. Indeed cardiac remodelling and LV hypertrophy can develop in 
the absence of hemodynamic stress, such as from metabolic or hormone disruption, 
genetic factors, or may be pathologically idiopathic. Detailed studies in cultured 
cardiomyocytes and animal models in vivo have allowed the characterization of many 
pro-hypertrophic pathways. The following is a brief summary of these complex 
signalling pathways, reviewed by [211, 219, 227]: Angiotensin II (AngII), Endothelin-
1 (ET-1), and catecholamines bind G-protein coupled receptors (GPCR) to activate 
protein kinase C through the activation of phospholipase C (PLC), or Ca2+ influx, 
leading to HDAC translocation to the cytosol, and MEF2 transcription. HDAC 
translocation and activation of hypertrophy may alternatively be stimulated by the 
calcium-calmodulin-CaMK signalling pathway. Receptor tyrosine kinases mediate 
neuregulin, epidermal growth factor, and insulin-like growth factor-1 (IGF-1) 
signalling via the Rho/Rac1/Ras pathway, leading to MEK1/2-ERK1/2, and also 
MEK5-ERK5 activation of hypertrophy. TGFβ activates MEK3/6-p38 signalling and 
also MEK4/7-JNK signalling. Increased intracellular Ca2+ leads to calmodulin-
dependent calcineurin activation and dephosphorylation of NFAT (calcineurin- 
nuclear factor of activated T-cells). NFAT then translocates to the nucleus (a process 
accelerated by ERK) where it upregulates hypertrophic genes (GAGA4, NFAT, AP1). 
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POH is associated with the significant increased expression of extracellular 
matrix constituents leading to interstitial fibrosis, impaired LV compliance, and 
diastolic dysfunction; whereas VOH is associated with a decreased expression of the 
ECM and overall dissolution of existing collagen by the matrix metalloproteinases 
(details of ECM regulation in the myocardium in various pathologies will be discussed 
in section 1.5). Expansion of the ECM in LV remodelling is a critical event in non-
ischemic heart disease, and there is growing appreciation of the direct role the ECM 
plays in activating pro-hypertrophic signalling. ECM-integrin interaction may play a 
crucial role in transducing hemodynamic/mechanical load into biochemical events 
through ‘outside-in’ cascades: mechanical stress first exerts force upon the 
cardiomyocytes and the ECM  which then stresses the focal adhesion complex and the 
integrins embedded in the cell membrane, thereby initiating intracellular signalling 
events such as activation of the pro-hypertrophic Ras-Raf-ERK1/2 pathway [190, 
197]. The α3β1 integrin heterodimer expressed in cardiomyocytes can bind numerous 
ECM ligands including collagen I, fibronectin, and laminin, and indeed the integrin 
subunits α1, α5, β1 and β3 are upregulated and/or activated by hypertrophy and PO 
[228-231]. VO however is associated with a progressive decrease in integrin 
expression [205]. Clearly, mechanisms mediating cardiac hypertrophy and cardiac 
fibrosis are intertwined in the overloaded myocardium. In the following section the 
effects of ventricular unloading on the remodelled/hypertrophic heart will be 
discussed. 
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1.4.3 Reverse remodelling 
The remodelling events induced by PO and VO serve to offset systolic or 
diastolic wall stress, respectively, to preserve cardiac function (see section 1.4.1). 
However, numerous in vivo studies have demonstrated that when cardiac remodelling 
is avoided through genetic modification or pharmacological treatment, normal 
function is retained despite the induction of PO. Indeed, the Framingham Heart 
Study identified echocardiographic LVH as a significant risk factor for cardiovascular 
morbidity and death, even after normalization for other significant risk factors such 
as blood pressure, cigarette use, and cholesterol profile [232]. Accordingly, anti-
hypertensive therapies (beta-blockers, ACE inhibitors and angiotensin II receptor 
antagonists (ARBs)) have been enormously successful in delaying the onset of 
maladaptive remodelling. Congestive heart failure (CHF) patients have benefitted 
from aggressive surgical techniques such as valve replacement and left ventricular 
assist device (LVAD) implantation, both of which directly alleviate LV PO [233, 234]. 
Indeed, accumulating clinical and experimental evidence has demonstrated 
restoration of cardiac function and regression of LV remodelling following LV 
unloading, a process now commonly termed reverse remodelling [235, 236]. 
Recent in vivo studies have begun to characterize the process of reverse 
remodelling in greater detail. LV unloading is achieved through removal of the 
constricting aortic band (debanding), and leads to reverse remodelling of the left 
ventricle, restoration of normal cardiac function [237-239], activation of a unique gene 
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expression profile [240], and normal pressure-volume relationships as long as 
debanding is performed before the heart enters decompensated failure [241]. Along 
with the regression of cardiomyocyte hypertrophy, debanding and the cessation of 
AngII infusion increased autophagic flux [242, 243].  
However, less is known regarding changes to the ECM following unloading of 
the left ventricle. Increased fibrosis is universally regarded as a negative indicator of 
cardiac function and recent evidence using Doppler echocardiography and strain 
analysis has demonstrated the detection of early diastolic dysfunction in heart failure 
patients due to early upregulation of collagen in the myocardium. ECM expansion is 
typically viewed as a unidirectional progression [202, 244, 245]. In fact, evidence from 
recipients of valve replacements indicated the expansion of fibrosis despite LV 
unloading, leading to worsening diastolic indices of myocardial stiffness [246]. Indeed, 
debanding was also shown to differentially regulate the expression of collagen 
isoforms in in vivo [239, 247], and our studies (chapter 3) provide a clear structural 
picture of the 3-dimensional architecture of collagen networks in the debanded 
myocardium. We show that debanding results in the loss of the less compliant large 
collagen fibres, but also leads to an expansion of small fibre fibrosis which may have 
negative long-term implications for cardiac function. 
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1.5 Cardiac fibroblasts and the extracellular matrix regulation 
1.5.1 Structure and function of the extracellular matrix 
The cardiac extracellular matrix (ECM) is a highly organized interstitial network of 
structural proteins that forms a scaffold to perform functions such as tethering 
adjacent cardiac myocytes. It serves a vital role in the diseased myocardium, 
providing stress bearing support during overload, and reinforcing weak areas to 
prevent rupture in ischemic heart disease, but contributes to myocardial stiffness in 
later stages of heart failure. The cardiac ECM is separated into three layers. The outer 
layer, the epimysium, surrounds the myocardium and lies below the endothelial layer 
of the epi- and endo-cardium. The perimysium is a sheath of connective tissues 
consisting of tendon-like extensions of the epimysium. The perimysium aggregates 
myocytes into muscle fibres, bears shearing forces during contraction and relaxation, 
and minimizes the dissipation of force generated by cardiomyocytes. The endomysium 
surrounds and connects neighbouring myocytes and the intramuscular vasculature 
[248]. It is proposed that myocardial forces are transmitted through the endomysial 
ECM to the internal cytoskeleton of individual myocytes via ECM-integrin 
interactions at the cell surface [190, 228] (see section 1.4.3). All three layers of the 
ECM are composed mostly of collagen type I which has a tensile strength greater than 
that of steel [248], and allows for the mechanical co-ordination of forces generated by 
the myocytes. The ECM also contributes to LV expansion during diastole as coiled 
fibres release potential energy stored through compression in systole [249]. The 
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cardiac ECM is composed primarily of fibrillar collagens: collagen type I (~85%), type 
III (~10%), and type IV (~5%), although the endomysial and perimysial layers also 
have a percentage of elastin, allowing more flexibility during each cardiac cycle [250-
252].  
The ECM is not a static structure, rather it is a dynamic, complex environment 
containing bioactive matrix proteins, signalling molecules, and various cell types. 
With a half-life of approximately 80-120 days in the healthy myocardium, the ECM 
undergoes a slow rate of turnover at approximately 0.6% per day. In disease 
conditions, changes in the composition and structure of the ECM in response to 
environmental cues and/or tissue injury have been shown to play an important role 
in the process of myocardial remodelling, and the progression of heart failure [249, 
253]. Indeed, changes to the cardiac ECM may lead to, or be the result of, various 
myocardial pathologies, and certainly, the ECM plays a large role in the compensation 
and decompensation phases of cardiac remodelling [191, 248-250]. 
1.5.2 Cardiac fibroblasts and myofibroblasts 
The importance of cardiac fibroblasts in the heart cannot be understated, as 
they play a vital role in heart development (the earliest organ to form in the incipient 
embryo), and in the adaptive/reparative response to stressors pushing the adult heart 
to failure. Cardiac fibroblasts (CF) constitute 60-70% of the cell population in the 
myocardium and participate in the pathogenesis of heart disease as the principle 
regulators of the cardiac ECM. Morphologically, CFs are relatively flat, have spindle 
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projections, and are localized to the endomysial collagen layers between the much 
larger cardiomyocytes. Developmentally, CFs originate from proepicardial cells that 
migrate throughout the embryonic heart, reacting to a delicate balance of signalling 
factors (e.g. fibroblast growth factor, platelet derived growth factor-β etc..) to undergo 
epithelial-to-mesenchymal transition (EMT), then differentiation into CFs. There is 
also growing evidence that embryonic cardiac fibroblasts may originate from 
endocardial cells and undergo endocarial-to-mesenchymal transition (EndMT) [254]. 
Embryonic CFs throughout the developing heart begin to construct a comprehensive 
three dimensional myocardial network, and are responsible for stimulating 
cardiomyocyte growth and proliferation during ventricular compaction until birth 
[255, 256]. Interestingly, in vitro co-culture of adult cardiomyocytes (ACM) with 
embryonic CFs induces ACM proliferation, whereas co-culture of ACM with adult CFs 
induces ACM hypertrophy, consistent with the well established post-natal shift in 
cardiac growth from embryonic hyperplasia to adult hypertrophy and demonstrating 
the importance of CF-CM crosstalk [256]. As the fetal heart grows in utero it is 
exposed to a hypoxic, dynamic environment [257]. The principle metabolic 
requirement of the fetal heart are carbohydrates; it’s ability to oxidize fatty acids is 
limited [257]. The gene pattern expressed during this time, meeting the growing 
heart’s metabolic demands and hemodynamic stresses, is termed the fetal gene 
program, and is a well known reparative mechanism re-initiated in the heart to 
compensate for excessive stress in the adult myocardium [210]. Following the 
maturation of the heart, CFs again play a principle role in the compensatory 
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mechanism sustaining heart function against the substantial increase in systolic 
pressures following birth by modifying the ECM to efficiently distribute mechanical 
stress to the ventricles undergoing severe hypertrophy [258]. This dynamic period 
lasts for a short time after birth, after which mature CFs lie largely quiescent in the 
normal heart but continue to regulate basal ECM turnover, maintain signalling 
interactions with cardiomyocytes, and retain their migratory ability to effectuate a 
response to stressors [259, 260].  
In the progression of heart disease, CFs become active, and along with other 
precursor cells, differentiate into myofibroblasts (myoCF), a fibroblast-smooth muscle 
cell hybrid that actively regulates the ECM, become a key source of bioactive agents, 
and develop contractile apparatus to aid in preventing LV rupture upon loss of 
cardiomyocytes to apoptosis or necrosis [174, 231, 261]. It has been proposed that 
oxidative-stress induced cardiomyocyte necrosis is a mechanism preceding and 
stimulating myoCF differentiation [250, 262]. The current understanding is that 
myofibroblast (myoCF) progenitor cells include more than just resident fibroblasts; 
rather, endothelial and epithelial cells (following EndMT and EMT, respectively), 
smooth muscle cells, and bone-marrow derived cells (e.g. fibrocytes, monocytes) are 
also now believed to contribute to the pool of pro-myoCF cells [174, 254]. Owing to the 
diversity of parental cell lineages, myoCF differentiation is a complex process that 
varies by cell type and stimulus, although AngII, TGFβ, and mechanical force are 
three well established mechanisms [174]. AngII is significantly upregulated with 
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heart disease, functions through GPCR signalling, and stimulates ERK and p38 
signalling [263], and PARP-1 activity [186]. Inhibition of p38 attenuates AngII 
induced myoCF differentiation [264], while AngII stimulation induces TGFβ and Col 
I expression from CFs [265, 266].  
TGFβ is a primary and potent mediator of myoCF differentiation that is 
upregulated and secreted into the ECM by mesenchymal cells, macrophages, 
monocytes, and resident CFs [174]. TGFβ signalling is mediated by the TGFβ 
receptors TBFβRI/RII which initiate SMAD2/3 phosphorylation which, upon 
activation, complexes with SMAD4. TGFβ-SMAD2/3 signalling leads to myoCF 
differentiation, and αSMA, Col I, Col VI, and MMP expression. TGFβ also initiates 
myoCF differentiation through p38 signalling via TGFβ/RII [174].  
Interestingly, mechanical stretch has been shown to upregulate a number of 
signalling cascades including angiotensionogen expression and p38 phosphorylation 
[267], as well as TGFβ expression and activity in cardiac fibroblasts and 
cardiomyocytes [268-270]. When retained in the ECM, TGFβ1 forms a complex with 
latent TGFβ binding proteins and fibrillin. In the progression of myocardial fibrosis, 
αSMA mediated myoCF contraction of the increasingly rigid ECM liberates TGFβ 
from this intracellular pool of signalling proteins, inducing a positive feedback loop 
which further stimulates myoCF differentiation, and secretion of the ECM and 
myoCF derived cytokines [174]. 
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Rather than being the final step in cardiac remodelling, CFs, myoCFs, and 
reactive fibrosis are considered integrated, essential players in the adaptive response 
to pressure overload [271], and indeed, myoCFs have been shown to secrete numerous 
cytokines heavily involved in cardiac remodelling: TNFα, IL-1β, IL-6, TGFβ, Ang II, 
ET-1, the NFF (ANP, and BNP), and VEGF are all part of the CF and/or myoCF 
secretome. Activation of CFs and subsequent upregulation of the myoCF secretome is 
largely accepted as an early adaptive event to maintain homeostatic cardiac function; 
however, prolonged presence of myoCF and chronic deposition of collagen in the ECM 
is considered a detrimental, mal-adaptive mechanism leading to poor clinical 
outcomes [272].  
1.5.3 Collagen synthesis and regulation 
The collagen family comprises over 18 distinct isoforms of collagen with 
diverse physical characteristics whose relative abundance varies from tissue to tissue 
[273]. Interstitial collagen consists of 3 polypeptide α-chains, composed of large helical 
domains, which contain a high proportion of hydroxyproline[273]. Collagen type I (Col 
I) and collage type III (Col III) are the major structural components in the cardiac 
extracellular matrix [248]. Col I and III are secreted by CFs and myoCFs as pro-
collagen precursors, with N-terminal and C-terminal propeptides that are cleaved 
leaving short non-helical regions at either end suitable for intermolecular crosslinks 
[274]. Pro-collagen molecules are released into the extracelluar space were the 
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enzyme lysyl oxidase mediates covalent crosslinking of collagen molecules into rigid, 
mature fibrils [275]. 
While Col I accounts for approximately 85% of all collagen in the myocardium 
[252], the much less rigid Col III comprises the majority of the remaining collagen 
content and helps confer elasticity to the myocardium. There are numerous methods 
to quantify the relative ratio of collagen isoforms within the heart (quantitative PCR, 
western blot, ELISA, masson’strichrome staining), but two of the most exemplary 
techniques to image the structure of the collagen ECM are picrosirius red staining 
coupled with polarized light microscopy (picrosirius red detects of the high 
hydroxyproline content in collagen, while polarized light microscopy permits the 
distinction of the Col I and Col III with high precision [276]), and direct imaging using 
scanning electron microscopy (SEM). In SEM micrographs, Col I appears thick and 
rigid, while Col III appears much finer, and is present in significant quantity in the 
healthy myocardium (see figure 3.1). It is believed that changes in the relative ratios 
of Col I:Col III, as well as alterations in the organization and cross-linking of the 
collagen matrix, influence myocardial compliance. Specifically, late-stage LV 
remodelling in POH is associated with elevated Col I which promotes myocardial 
stiffness, resulting in impaired contractile function [252, 253]. As discussed 
previously, diabetic cardiomyopathy (section 1.1.3), and aortic valve stenosis (section 
1.3.1) are associated with increased LV fibrosis, decreased LV compliance, and cardiac 
dysfunction. Microscopic imaging analysis of dilated (idiopathic) cardiomyopathic 
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hearts showed a significant increase in Col I:Col III ratio compared to normal 
samples, localized to the endomysial layer surrounding the cardiomyocyte fibrils [277, 
278]. Similarly, collagen type I expression [279] are significantly increased in patients 
with essential hypertension. 
In addition to Col I and Col III, the ECM hosts a number of non-fibrillar 
collagens such as collagen IV, V, and VI, as well as other structural proteins such as 
laminin, fibrillin, and elastin (table 1.4) that form the in situ adhesion substrate for 
cardiomyocytes and cardiac fibroblasts [273, 280].Cellular behavior is in part dictated 
by the relative ratio of these structural proteins in the substrate:  Col I and III 
increase CF proliferation and migration Col VI increases myoCF differentiation and 
decreases migration, and Col V imparts anti-proliferative effects on smooth muscle 
cells [281]; Col IV induces smooth muscle cell differentiation [280]; elastin can 
influence smooth muscle cell proliferation and phenotype [282]. It is hypothesized 
that the increased expression of the basement membrane collagens (Col IV, V) serves 
to slow the migration of several cell types, and to aid in maintaining structural 
integrity in the post-MI heart [280]. 
Cardiac fibrosis occurs with high incidence in arrhythmetic myopathies [261]. 
Recent data has recognized the importance of non-myocyte reorganization in the 
pathology of electrophysiological remodelling leading to cardiac arrhythmias [261]. 
Although CFs are typically considered non-excitable cells, their depolarized resting 
membrane potential is lower than that of cardiomyocytes, potentially allowing 
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electrical signals to pass between cardiomyocytes through intervening CFs with some 
impedance [261]. However, while the heterogeneity of fibroblasts across different 
areas of the heart makes definitive conclusions regarding the participation of 
fibroblasts in electrical signalling elusive [261], expansion of the collagen 
extracellular matrix in POH and MI has been shown to play a detrimental role in the 
myocardial electrical coupling [283]. Various patterns of fibrosis (compact, patchy, 
interstitial, diffuse) have differential impacts on the propagation of electrical signals 
between myocytes. Patchy or severe fibrosis, where myocytes are separated by a-
cellular regions of collagen, poses the greatest risk for arrhythmias, as electrical 
propagation is forced to take a circuitous route through the tissue slowing conduction 
velocities [283]. Fibrosis also promotes uncoordinated triggers originating in aberrant 
myocytes, which then propagate to and depolarize the few neighbouring myocytes 
leading to fibrillation [283]. 
Clearly, the collagen ECM plays a significant, initially adaptive and 
subsequently detrimental role in the diseased myocardium. In the next section, 
regulation of the ECM will be discussed. 
Table 1.4: Structural proteins in the ECM. 
Adapted from [273, 280, 282] 
Structural Protein Location Role 
Collagen I (Col I) Interstitium Structural 
Collagen III (Col III) Interstitium Structural 
Collagen IV (Col IV) Basement membrane Cell attachment, substrate filter 
Collagen V (Col V) Interstitium Structural, substrate filter 
Collagen VI (Col VI) Interstitium Structural 
Laminin Basement membrane Cell attachment 
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Elastin Interstitium, connective 
tissue 
Elastic recoil and resilience 
Fibrillin Interstitium, connective 
tissue 
Elastic recoil and resiience 
 
1.5.3 Matrix metalloproteinases and tissue inhibitors of MMPs 
The rate of extracellular matrix turnover in the normal heart is mediated by 
the concerted effects of i) the matrix metalloproteinases (MMPs) which have the 
ability to degrade structural proteins, ii) the tissue inhibitors of metalloproteinases 
(TIMPs) and iii) the continual expression of structural proteins principally by cardiac 
fibroblasts, with smaller contributions from cardiac myocytes and other cell types 
(table 1.5) [252].  
The expression of matrix metalloproteinases (MMPs) is dramatically 
upregulated in response to both acute and chronic stresses such as myocardial 
infarction and hypertension [192, 284]. Patients suffering from dilated 
cardiomyopathy were shown to have increased ventricular MMP-2 and MMP-9 
activity [285], while spontaneously hypertensive rats with heart failure were found to 
have elevated MMP-2 activity when compared against normotensive controls [286]. 
By contrast mice lacking MMP-2 or MMP-9 showed a decrease in infarction-induced 
left ventricular hypertrophy [287, 288], while exogenous MMP-2 treatment was found 
to dilate and decrease the cardiac tensile strength of ventricular preparations from 
spontaneously hypertensive rats [289]. 
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MMPs are under transcriptional regulation by a number of factors, although 
two major cis-acting elements are found in the majority of the MMP promoters: 
polyoma enhancer A binding protein-3 (PEA-3) which interacts with the Ets family of 
transcription factors, and activator protein-1 (AP-1) which interacts with the Fos and 
Jun family of transcription factors [253]. The MMP2 promoter, however, lacks both of 
these elements possibly indicating constituitive expression of the MMP2 protein, 
although MMP2 expression may be increased in the failing heart after MI [290].  
To protect the cell from damage, MMP’s are typically synthesized as inactive 
zymogens, and must undergo post-translational modifications to become 
proteolytically active[192].Membrane type 1 matrix metalloproteinase (MT1-MMP, 
also called MMP14) is a zinc dependent MMP that plays an important role in peri-
cellular ECM digestion leading to cell migration and tissue invasion [291]. MT1-MMP 
is itself synthesized as a pro-peptide, activated through removal of the inhibitory pro-
domain in a two-step degradation/cleavage mechanism mediated by the protease furin 
[292]. Mature, membrane bound MT1-MMP’s peri-cellular activity may be regulated 
through control of its internalization and trafficking via ubiquitination [293] of its 
intracellular domain. MT1-MMP’s degredative ability may furthermore be 
supplemented through activation of MMP2 and MMP13, leading to processing of 
collagen substrates (e.g. collagen IV) that MT1-MMP is incapable of degrading [291] 
(table 1.5). Cell surface activation of MMP2 requires the homo-dimerization of MT1-
MMP which then binds an MMP2-TIMP2 complex leading to cleavage of the MMP2 
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pro-domain and the liberation of active MMP2 [294, 295]. Recently, we demonstrated 
that adiponectin stimulates MT1-MMP cell surface localization, MMP2 activation and 
cardiac fibroblast migration through the phosphorylation of AMPK [108]. 
Upstream activators of MMP expression include many of the common 
cytokines involved in the inflammatory response, cardiac dysfunction and metabolic 
disorders: TNF-α, IL-1β, ET-1, oxidative stress, sympathetic activation, TGF-β, and 
mechanical stretch [296]. Accordingly, MMP activity is upregulated in many 
conditions including diabetic cardiomyopathy, PO and VO, and also in unique animal 
models such as the SHR [251]. 
The ECM regulatory function of the TIMPs is primarily as endogenous 
inhibitors of the MMPs, although, as described above, TIMP2 is involved in the 
activation of MMP2 via MT1-MMP at the cell surface [253]. As such, a gerneral 
increase in TIMP expression may serve to limit MMP activity and induce collagen 
accumulation in the myocardium. Accordingly, in the SHR model TIMP-4 expression 
is increased in compensated LVH, while the progression of CHF is characterized by 
an increase in MMP2 activity and TIMP4 expression is decreased in [251]. Similarly, 
TIMP expression is reduced in end-stage DCM which is associated with increased 
ECM degradation and LV dilation [251]. Evidence suggests that TIMP2 and 4 may 
have opposing roles in heart failure. TIMP2, the activator of MMP2, was found to 
have a much higher specificity than the other TIMPs for MMP2 [294], while TIMP4 
has a greater general affinity for MMPs than TIMPs 1 and 2 [297], suggesting that 
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increased TIMP2 expression may facilitate increased MMP2 activation, while 
increased TIMP4 may signify an increase in fibrosis.  
While MMPs are typically active in the interstitium, TIMP-4 and MMP2 were 
shown to accumulate within cardiomyocytes following I/R injury [298]. Indeed, active 
forms of MMP2 and MMP9 have been found intracellularly in cardiomyocytes in 
patients with dilated cardiomyopathy, which may lead to degradative loss of 
sarcomeres and impaired contractile function [290]. 
Table 1.5: ECM substrates of MMPs, and activity change with LVH or CHF. 
LVH: LV hypertrophy. Defined as increased LVPWd with normal EF. CHF: congestive heart 
failure. Adapted from [251]. 
Enzyme Alternate name ECM substrate Δ in LVH Δ in CHF 
MMP1 Collagenase – 1 Collagens (I, II, III, VII, VIII, & X), 
gelatin, proteoglycan link protein 
- ↑ 
MMP2 Gelatinase A Collagens (I, IV, V, VII, X & XIV), 
gelatin, elastin, fibronectin, laminin 
↑ ↑↑ 
MMP8 Collagenase – 2 Collagens (I, II, III, V, VII, VIII, & X), 
gelatin, aggrecan 
- - 
MMP9 Gelatinase B Collagens (IV, V, VII, X, & XIV), 
gelatin, aggrecan, elastin, fibronectin 
↑ ↑↑ 
MMP14 MT1-MMP Collagens (I, II and III), casein, 
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1.6 Research Objectives 
The rise of the obesity and diabetes epidemic has caused an increase in worldwide 
cardiovascular risk. There is a great need to determine the endocrine factors linking 
these serious pathologies.  
The adipokine adiponectin has gained significant interest as a potential 
regulator of cardiac remodelling in heart disease. Accumulating clinical and 
experimental evidence has suggested that adiponectin may play an important role in 
the progression of heart failure, but the role of adiponectin in the development of 
cardiac fibrosis, a negative indicator of heart disease outcome, is currently uncertain. 
As such, a detailed comparison of changes to the extracellular matrix in adiponectin 
null and wild-type mice following the induction of pressure overload will contribute 
to our understanding of adiponectin action in heart disease and help to resolve 
conflicting data within the field. Furthermore, little is known regarding adiponectin 
stimulated regulation of the extracellular matrix and cardiomyocyte hypertrophy; 
insight into adiponectin mediated signalling pathways in cardiac fibroblasts and 
cardiomyocytes is needed. Lastly, the normal progression of fibrosis following the 
induction of pressure overload has been established, however little is known 
regarding changes to the fibrotic myocardium following unloading of the left ventricle. 
A thorough study of the changes to the extracellular matrix in regressive cardiac 
remodelling will give valuable insight into the long term clinical consequence of 
episodes of transient hemodynamic overload and cardiac fibrosis.  
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The above research objectives lead me to my four studies listed below: 
 
Study 1: Adiponectin deficiency alters the progression of ECM remodelling 
following the induction of pressure overload 
 
Study 2: Adiponectin mediates ECM remodelling via the APPL1-AMPK 
signalling axis in cardiac fibroblasts  
 
Study 3: Myocyte Enhancer Factor-2 binding is attenuated in adiponectin 
deficiency following pressure overload, and is upregulated by 
adiponectin stimulation of cardiomyocytes 
 
Study 4: A detailed analysis of reverse cellular, structural and functional 
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2.1 Abstract 
 Adiponectin, circulating levels of which are reduced in obesity and diabetes, 
has been shown to mediate cardiac remodelling events in response to pressure 
overload (PO). Fibrosis, a principle feature of PO is the progressive expansion of the 
extracellular matrix (ECM) which significantly contributes to changes in cardiac size, 
structure and function leading to heart failure. In this study, we performed a detailed 
analysis of progressive cardiac ECM remodelling in adiponectin knockout (AdKO) and 
wild-type (WT) mice following the induction of PO via minimally invasive transverse 
aortic banding. AdKO mice displayed an increased extent of basal cardiac fibrosis. 
Expansion of the ECM observed in WT mice after 2 weeks of PO, determined by 
scanning electron microscopy, Masson’s trichrome staining and increased collagen-
1α1 and 3α1 expression, was not observed in AdKO mice until after 4 weeks of PO. 
Similarly, myocardial expression of principle ECM regulatory genes (collagens, 
MMPs, and TIMPs) differed between genotypes in response to PO. Circulating Ad 
levels and myocardial Ad mRNA were reduced after 4 weeks of PO, whereas Ad 
protein detected in cardiac homogenates was increased at this time. Direct 
stimulation of primary cardiac fibroblasts with Ad induced a transient increase in 
total collagen (picrosirius red staining) and collagen III (immunofluorescence) 
synthesis, as well as enhanced MMP2 activity via gelatin zymography. Ad also 
enhanced fibroblast migration and attenuated angiotensin-II induced differentiation 
to a myofibroblast phenotype.  
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In conclusion, these data indicate that Ad deficiency delays ECM expansion in 
response to PO. Increased myocardial bioavailability of Ad in WT mice may mediate 
immediate ECM regulation following PO. The direct effects of Ad on fibroblasts to 
mediate collagen and MMP expression play an important role in the pathogenesis of 
cardiac fibrosis.  
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2.2 Introduction 
 The physiological significance of myocardial ECM regulation by adipokines in 
diabetes and obesity has been well established [128, 148, 299]. In particular, 
regulation of cardiac remodelling by adiponectin is thought to be of great significance 
[148]. Adiponectin is present at high circulating levels (in the range 2 to 20 ug/ml) in 
normal individuals but levels are reduced in heart disease, diabetes, and obesity  [148, 
300]. Recent discovery of heart specific adiponectin production and regulation in 
various clinical states of heart disease has led to the framing of adiponectin as a 
‘cardiokine’ and an expanded emphasis on the role of adiponectin in the progression 
of cardiac remodelling [112]. The adiponectin knockout mouse (AdKO) has proven to 
be an extremely useful model in this regard, and early studies showed that 
adiponectin deficiency exacerbated pressure overload induced cardiac remodelling 
[116, 131, 157]. Recently however, similar studies indicate that adiponectin deficiency 
plays a protective role against the development of adverse cardiac remodelling events 
leading to heart failure [161-163]. Meta-analysis of clinical studies correlating 
adiponectin with various heart disease outcomes has been similarly inconclusive [133, 
301, 302]. Clearly, more insight into the mechanism of adiponectin action in the 
pathogenesis of PO induced cardiac remodelling is needed. 
 Cardiac ECM remodelling plays a critical role in the adaptation to 
haemodynamic stressors and ultimately in the progression to heart failure [299]. In 
mouse models, induced left ventricular pressure overload (PO) is commonly 
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associated with collagen deposition as a reactive response of the myocardium to 
mitigate cardiovascular decompensation leading to failure. The transition from 
compensatory ECM support to detrimental fibrosis occurs as differentiated, 
hypersecretory myofibroblasts persist in the overloaded myocardium [250]. 
Remodelling of the myocardial collagen matrix is primarily mediated by matrix 
metalloproteinases (MMPs) [253]. The role of MMP isoforms in heart failure in 
diabetes and obesity is now well established [128, 303]. During the process of 
remodelling, MMPs are initially activated to reduce wall stress by increasing fibrillar 
collagen degradation, allowing LV dilation in response to increased work load. 
Ultimately, prolonged MMP activation adversely affects cardiac function since the 
ultrastructural collagen which is initially degraded by MMPs is replaced by poorly 
structured collagen [304]. Indeed, changes in MMP levels have been described in both 
human and a variety of animal models of heart failure [303, 304]. Chemical inhibition 
of MMPs has also been shown to attenuate left ventricular dilation and preserve 
function after surgical induction of infarction [287] and targeting MMPs is thought to 
have therapeutic potential although little is known regarding the regulation of 
collagen and MMPs in the adiponectin deficient heart. 
 The aim of our study was to conduct a detailed temporal investigation of 
cardiac ECM remodelling after PO in WT versus AdKO mice. We also investigated 
changes in cardiac adiponectin expression and content, and study the direct effects of 
adiponectin on various end points relevant to ECM remodelling in primary cardiac 
fibroblasts. 
- 60 - 
 
 
2.3 Materials and Methods 
Materials 
Recombinant full-length adiponectin was produced in-house as previously detailed by 
[121]. Dulbecco’s modified eagle’s medium (DMEM), trypsin, antibiotic/antimycotic 
and fetal bovine serum (FBS) were obtained from Gibco Laboratories (Life 
Technologies Inc., Burlington, ON, CA). All culture plates were BD Falcon™ brand 
and purchased from BD Biosciences (Mississauga, ON, CA. Anti-collagen antibodies 
were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA. TRIzol® 
Reagent was purchased from Ambion Inc. (Life Technologies Inc.), Alexa Fluor® 488 
goat anti-rabbit antibody was obtained from Molecular Probes (Life Technologies 
Inc.), and adiponectin primers were obtained from Invitrogen (Life Technologies Inc.).  
The FITC-labelled goat anti-mouse antibody was obtained from Jackson 
ImmunoResearch Laboratories, Inc. (West Grove, PA, USA). VECTASHIELD® 
mounting medium with DAPI was obtained from Vector Laboratories (Burlington, 
ON, Canada).RNeasy MinElute Cleanup and RT2 First Strand kits were purchased 
from QIAGEN Inc. (Mississauga, ON, CA). 3H-proline was purchased from Amersham 
Biosciences (GE Healthcare Lifesciences, Baie d’Urfe, QC, CA). Amicon Ultra-15 
Centrifugal Filter Units were obtained from EMD Millipore (Billerica, MA, USA). The 
Pierce BCA Protein Assay kit was purchased from Thermo Scientific (Fisher Canada, 
Nepean, ON, CA). The custom fibrosis PCR array was purchased from SABiosciences 
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(QIAGEN Inc.). LOOK silk black braided non-absorbable 6-0 USP sutures were 
purchased from Harvard Apparatus (Holliston, MA, USA), titanium ligation clips and 




Male C57BL6 (wt) mice (Charles River Laboratories, St. Constant, QC), 6 – 8 weeks 
of age, and house bred AdKO mice were randomly allocated to treatment groups. 
Animal facilities met the guidelines of the Canadian Council on Animal Care, and the 
protocols were approved by the Animal Care Committee of York University. Animals 
were acclimated a minimum of 5 days to a standard housing environment: 
temperature and humidity-controlled rooms (21±2oC,35-40%), with a daily 12:12h 
light-dark cycle (lights on at 0700) with access to regular chow diet ad libitum. 
 
Minimally Invasive Transverse Aortic Banding 
Under general anesthesia (IP Xylazine 0.15mg/g; Ketamine 0.03mg/g), the mouse is 
kept in a supine position and the fur on the ventral surface removed with a depilatory 
cream, and the surface sterilized with betadine. A medial cranio-caudal incision is 
made through the skin from the neck to the bottom of the rib cage, and the neck 
muscles, fat, and thyroid are retracted to expose the trachea down to the suprasternal 
notch. An incision is made through the suprasternal notch 2-3 mm down the rib cage. 
The transverse aorta is visualized under low magnification between the innominate 
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and left common carotid arteries. A titanium micro-ligation clip is applied across the 
transverse aorta using banding calipers calibrated to the width of a 26g needle. The 
sham surgery is performed as outlined above without the placement of the ligation 
clip. Upon completion of the procedure, the rib cage and skin are closed with silk 
suture, and the mice injected with Buprenorphine (s.c. 0.05 mg/kg) and placed face 
down on a warming pad until they awake. 
 
Tissue and serum collection. 
Mice were weighed and euthanized using cervical dislocation. Hearts were excised 
and perfused briefly with KCl to arrest the heat in diastole. Hearts were then weighed 
and divided for further analysis. Blood samples were collected at time of death, 
centrifuged (10,000 RPM, 5 min, 4oC) and the serum supernatant collected to analyze 
adiponectin content. 
 
Scanning electron microscopy.  
Heart tissue was fixed in 2% EM grade gluteraldehyde in 0.1M sodium cacodylate 
buffer pH 7.3 for 1 hour at room temperature, then stored in 0.1M sodium cacodylate 
buffer, pH 7.3, 0.2M sucrose until further processing. Fixed samples were chemically 
dehydrated in hexamethylsilazine, mounted on stubs  and sputter-coated  (Hummer 
VI Au/Pd 40/60) and examined with a  high-resolution scanning electron microscope 
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(Hitachi S-520) at an accelerating voltage of 20kV equipped with a passive image 
capture system (Hitachi, Quartz PCI Version 6) 
 
Tissue histology.  
Mid-ventricular cross-sections were fixed in 10% formalin solution for 1 hour then 
stored in 70% ethanol at 4oC until further processing. Fixed heart tissues were 
dehydrated to xylene and embedded in pure paraffin wax blocks. 
 
Isolation, Culture and Adiponectin Treatment of Neonatal Rat Cardiac Fibroblasts 
Neonatal cardiac fibroblasts (CFs) were isolated from 3 – 4 day old Wistar rats as 
previously described [121]. CFs were used at first passage for myofibroblast 
differentiation experiments, or passaged twice, grown to 100% confluence (or as 
otherwise indicated below) and then starved with serum-free DMEM for at least 3 
hours prior to treatment with recombinant full-length adiponectin (5.0 µg/ml). 
 
Western Blot Analysis 
Cell culture lysis and protein sample preparation was conducted according to methods 
detailed by [305]. Heart tissue homogenate preparation is detailed [306]. Primary 
anti-phospho-AMPKα (Thr172), anti-AMPKα, anti-APPL1, and anti-β-actin 
antibodies were used at 1:1000 dilutions, and appropriate HRP-conjugated secondary 
antibodies were used at 1:10,000 dilutions. Proteins were detected by 
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chemiluminescence, quantified by densitometry using Scion Image software (Scion 
Corp., Frederick, MD, USA) and then normalized to either β-actin or total AMPK 
protein levels as appropriate. 
 
RNA Isolation and Quantitative Real-Time PCR 
Total RNA was isolated from cultured CFs using TRIzol® Reagent according to the 
manufacturer’s instructions, and purified using the RNeasy MinElute Cleanup Kit to 
attain an A260/A280 ratio between 1.9 and 2.0. First-strand cDNA, synthesized from 1 
μg RNA using the RT2 First Strand kit, was used in a custom PCR array comprising 
96-well plates pre-coated with primers listed in table 1. Quantitative real-time PCR 
was conducted using a Chromo4™ Detection system (Bio-Rad Laboratories Canada 
Ltd., Mississauga, ON, CA) according to cycling conditions outlined by the PCR array 
manufacturer. Data were analysed using RT2 Profiler PCR Array Data Analysis 
software (Version 3.5; QIAGEN Inc.) and normalized to GAPDH mRNA expression. 
Adiponectin mRNA expression (forward: 5′-GCAGAGATGGCACTCCTGGA-3′; 
reverse: 5′-CCCTTCAGCTCCTGTCATTCC-3′) was analyzed by quantitative real-
time PCR using DyNAmo HS SYBR® Green qPCR kit (Finnzymes, Woburn, MA) with 
a Chromo4 Detection system and the following cycling conditions: Hot start: 95 oC for 
15 minutes; 35 cycles of: 95 oC for 30 seconds, 65oC for 30 seconds, 72 oC for 30 seconds; 
final extension: 72 oC for 10 minutes. 
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Wound Scratch Migration Assay 
Fibroblast migration in response to adiponectin treatment was assessed using the 
wound scratch assay as described previously [108]. Fluorescent images were obtained 
using an Olympus BX51 confocal microscope (Olympus, Seattle, WA, USA) with a 20 
x objective, and fibroblast migration was assessed as the closure of the scratch wound 
in arbitrary length units using Inkscape software (www.inkscape.org). 
 
MMP2 Activity By Gelatin Zymography 
Zymographic analysis of conditioned media from CFs grown in 6-well plates was 
performed as described previously [108]. MMP2 activity was quantified by 
densitometric analysis of degraded areas using Scion Image software (Scion Corp.). 
 
Collagen Quantification and Imaging 
Immunofluorescent imaging of intracellular and secreted collagen, and quantification 
of collagen synthesis (3H-Proline incorporation), and secretion (pirosirius red 
staining) was performed as described previously [108]. 
 
Statistical analysis 
Data are expressed as mean values ± SEM (n), where n represents the number of 
experiments conducted. Student’s t tests were used to determine significant 
differences (P < 0.05) between groups. All statistical analyses were conducted using 
SigmaStat 3.5 Software (Systat Software Inc., San Jose, CA, USA). 




Progression of myocardial fibrosis 
The collagen ECM was imaged in ventricular myocardial samples taken from 
WT mice following MTAB or sham surgery. Scanning electron micrographs following 
MTAB shows the increasing presence of small fibres from 3 days to 3 weeks, while 
large collagen bundles are seen 3 and 4 weeks following MTAB surgery (Fig 2.1). 
Detection of myofibroblasts through alpha-smooth muscle actin (α-SMA) staining was 
increased in pressure overload heart sections starting 3 days following surgery (Fig 
2.2).  
 
Adiponectin deficiency delays the myocardial fibrotic response to pressure overload 
AdKO mice exhibit an increased basal fibrosis observable through scanning 
electron microscopy (Fig 2.4A), but not masson’s trichrome staining (Fig 2.3A). This 
increased presence of Col III-like small fibres was associated with the increased 
prevalence of myofibroblasts in the sham AdKO myocardium (Fig 2.3B). Pressure 
overload failed to induce myocardial collagen accumulation in AdKO mice 2 weeks 
following MTAB surgery (Fig 2.3A). Accordingly, expression of collagen III and IV, 
MMPs and TIMPs were significantly downregulated in MTAB AdKO mice compared 
to sham AdKO mice after 2 weeks of PO (Fig 2.5). However, after 4 weeks of PO, 
myocardial collagen deposition (Fig 2.4A, 2.4B) and the fibrotic gene profile (Fig 2.5) 
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in AdKO mice was consistent with expected features of cardiac remodelling. 
Percentage of genes up/down regulated are indicated in pie-charts (Fig 2.5). Pattern 
of regulation between WT and AdKO is similar 4 weeks after MTAB surgery. 
 
Pressure overload retains adiponectin in the myocardium and induces adiponectin 
resistance 
ELISA detection of adiponectin in circulation was unchanged in WT mice after 
2 weeks, and slightly decreased after 4 weeks of PO when compared to respective 
sham groups (Fig 2.6A). Myocardial adiponectin mRNA was significantly decreased 
following 2 and 4 weeks of PO, while western blot analysis showed a significant 
increase in adiponectin protein in myocardial samples after 4 weeks of PO (Fig 2.6B). 
Expression of the adiponectin receptors (AdipoR1 and AdipoR2) and the adapter 
protein APPL1 was significantly increased 3 days following MTAB surgery. After 4 
weeks of pressure overload, AdipoR1, AdipoR2, APPL1 and APPL2 expression was 
decreased (FIG 3C). 
 
 
Adiponectin induces collagen synthesis and secretion from isolated cardiac fibroblasts 
Ad treatment significantly increased collagen synthesis (3H-Proline 
incorporation) and secretion (picrosirius staining) from isolated neonatal cardiac 
fibroblasts (NCFs) after 6 hours (Fig 2.7A), correlating with the increased detection 
of intracellular collagen I and III following Ad treatment (Fig 2.7B). Immunostaining 
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similarly showed increased accumulation of the collagen ECM assembled by cardiac 
fibroblasts in vitro following Ad treatment (Fig 2.7D). Rotated 3-dimensional stacks 
of collagen stained immunofluorescent images show the localization of the collagen I 
matrix above NCFs, whereas collagen III appears as thick vertical fibres between 
NCFs. Adiponectin also stimulated an increase in the active form of MMP2 detected 
by zymographic analysis of cardiac fibroblast conditioned media (Fig 2.7C).   
 
Adiponectin increases cardiac fibroblast migration and inhibits angiotensin II 
stimulated fibroblast to myofibroblast differentiation 
Ad treatment significantly increased cardiac fibroblast migration as assessed through 
the wound scratch assay (Fig 2.8B, C), while there was no change in fibroblast 
proliferation (3H-Thymidine incorporation) following adiponectin treatment (Fig 
2.8A). Fibroblast to myofibroblast differentiation, a principle event in the 
development of cardiac fibrosis, was significantly increased by angiotensin II 
treatment of isolated cardiac fibroblasts as assessed through increased expression of 
α-smooth muscle actin (SMA) via western blot analysis and immunofluorescent 
staining. Adiponectin pre-treatment significantly attenuated angiotensin II induced 
fibroblast to myofibroblast differentiation (Fig 2.8 D, E). 
 




Figure 2.1: Cardiac fibrosis is temporally regulated following PO.  
Representative scanning electron micrographs of isolated samples of WT mouse ventricles 
3 days, 1, 2, 3, or 4 weeks following sham or MTAB surgery, shown at 5000X or 10000X. 
Images shown are representative of 5 – 10 images of n = 4 to 6 mice per group 
 
  




Figure 2.2: Detection of myofibroblasts in the myocardium following PO.  
Immunofluorescent staining of α-smooth muscle actin indicating myofibroblasts in 
histological sections taken from WT mice 3 days, 1, 2, 3, or 4 weeks following sham or MTAB 
surgery. Myofibroblast positive cells appear bright green. Images shown are representative 
of 5 – 10 images of n = 4 to 6 mice per group. Right side images have been digitally expanded 
to show αSMA positive cells (white arrow heads). 
 
  




Figure 2.3: PO induces myocardial Ad retention and resistance.  
(A) Analysis of serum adiponectin by ELISA. Serum was collected at time of euthanization 
from AdKO or WT mice 2 or 4 weeks following sham or MTAB surgery. Values are 
represented as mean of 4 to 6 mice per group ± sem. (B) Western blot analysis of cardiac 
homogenate samples from Ad KO or WT mice 2 or 4 weeks following sham or MTAB surgery, 
quantified in the graph below alongside quantitative real-time PCR analysis of adiponectin 
mRNA obtained from cardiac homogenates isolated from AdWT mice 2 or 4 weeks following 
sham or MTAB surgery. (C) Quantiative real-time PCR analysis of AdipoR1, AdipoR2, 
APPL1, and APPL2 mRNA obtained from cardiac homogenates isolated from WT mice 2 or 
4 weeks following sham or MTAB surgery. Values are represented as average C(t) fold sham, 
where sham is set to 1. Values are average of n = 3 to 5 mice per group ± sem. 
 




Figure 2.4: Adiponectin deficiency is associated with increased basal fibrosis.  
Representative scanning electron micrographs of isolated samples of Ad KO or WT mouse 
ventricles 2 or 4 weeks following sham or MTAB surgery, shown at 2000X (A) or 5000X (B). 
Images shown are representative of 5 – 10 images of n = 4 to 6 mice per group. 
 
  




Figure 2.5: Fibrosis and myofibroblast expression is delayed in AdKO mice.  
A) Masson’s trichrome staining of histological sections taken from AdKO or WT mice 2 or 4 
weeks following sham or MTAB surgery. Cardiomyocytes are stained red, nuclei are stained 
black, and collagen is stained blue. (B) Immunofluorescent α-smooth muscle actin staining 
of myofibroblasts in histological sections taken from AdKO or WT mice 2 or 4 weeks 
following sham or MTAB surgery. Cells with strong α-smooth muscle actin staining appear 
bright green. Arrows indicate example positive cells. Images shown are representative of 5 
– 10 images of n = 4 to 6 mice per group.  
 
  




Figure 2.6: Gene regulation of ECM markers following PO.  
Analysis of collagen, MMP, and TIMP expression from Ad KO or WT mice 2 or 4 weeks 
following MTAB surgery, represented as average C(t) value fold sham, where sham is set to 
1. Values are average of n = 4 to 6 mice per group. * = p < 0.05 
 
  




Figure 2.7: Adiponectin Increases Collagen Synthesis and Secretion, and MMP2 activation 
from Cardiac Fibroblasts.  
(A) Intracellular pro-collagen synthesis was assessed by 3H-proline incorporation following 
adiponectin treatment (5 μg/mL) for 6, 24, or 48 h. Data represent mean values ± SEM from 
n = 3 experiments using 3 wells per group for quantification. Total secreted collagen was 
measured in fibroblast conditioned media following adiponectin treatment for 6, 24 or 48 h 
by picrosirius red staining. Data represented as mean arbitrary units ± SEM from n = 7 
experiments.  (B) Immunofluorescent images of intracellular collagen I (red) and collagen 
III (green) synthesized in cardiac fibroblasts at 60x magnification. Cells were treated with 
adiponectin for 6, 24 and 48 h. Representative images from n = 3 experiments are shown. 
(C) MMP2 activation was analyzed by gelatin zymography in conditioned media collected 
from 6, 24 and 48 h adiponectin treated (5 μg/mL) fibroblasts. A representative gel, 
indicating inactive ( ̴ 68 kDa) and active ( ̴ 62 kDa) MMP2 isoforms, is also shown in (C). 
MMP2 activity represents the MMP2 active/inactive ratio. Data represent mean values ± 
SEM from n = 3. (D) Immunofluorescent images of extracellular collagen I (green) and 
collagen III (red) secreted from cardiac fibroblasts at 60x magnification. Cells were treated 
with adiponectin for 3 days. Cell nuclei were also stained with DAPI (blue). Representative 
images from n = 3 experiments are shown. Below, 3-dimensional stacks of Ad treated NCFs 
immunostained for Col-I and Col-III were rotated to show relative vertical orientation of 
nuclei (DAPI) and collagen (green). Arrow head indicates coverslip. 
 




Figure 2.8 Adiponectin increases fibroblast migration, and inhibits fibroblast to 
myofibroblast differentiation 
(A) Fibroblast proliferation was assessed by 3H-thymidine incorporation following 6 or 24 
hours adiponectin treatment. Data represent mean values ± SEM from n = 3 experiments. 
(B) Quantification of cell migration, shown in (C), examined using the wound scratch 
assay in adiponectin treated (5 μg/mL) cardiac fibroblasts Cell nuclei were stained with 
DAPI and imaged using fluorescent microscopy under a 20x objective. Migration was 
quantified as the reduction of the wound width. Data represent mean values ± SEM from 
n = 3 experiments, using 7-10 images per group for quantification. *Significant difference 
(p < 0.05) from untreated control. (D) Western blot analysis of cardiac fibroblast cell 
lysates treated with adiponectin (5 μg/mL) and/or pre-treated with AngII as indicated. I 
Immunofluorescent staining for αSMA in cardiac fibroblasts treated with adiponectin (5 
μg/mL) and/or pre-treated with AngII as indicated. 
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2.5 Discussion 
In this study we sought to characterize the temporal progression of cardiac 
fibrosis induced by pressure overload in the presence or absence of adiponectin. The 
well characterized non-ischemic myocardial fibrotic response to pressure overload is 
the robust increase in Col I/Col III ratio aimed to support the overloaded myocardium 
and delay the progression towards decompensated heart failure. Whereas previous 
studies have relied on masson’s trichrome staining or collagen mRNA as measures of 
fibrosis, herein we add a visual temporal analysis of developing myocardial fibrosis 
using scanning electron microscopy. Our characterization of the progression of 
fibrosis in WT mice showed an acute increase in small-fibre fibrosis 3 days after 
MTAB surgery, morphologically consistent with the increased deposition of Col III, 
followed by the appearance of thick Col I fibres starting 2 weeks after MTAB surgery. 
Accordingly, there is a significantly increased presence of myofibroblasts from 2 to 3 
weeks following MTAB. The conspicuous absence of myofibroblasts 4 weeks after 
MTAB may be a result of the previously characterized fibroblast apoptotic response 
[258, 307], a known protective mechanism limiting adverse fibrosis. 
MTAB surgery failed to induce myocardial collagen deposition or activation of 
ECM regulatory genes in the AdKO myocardium, and instead we observed a 
significant downregulation of MMPs and TIMPs. Indeed, while this may have led to 
decreased collagen turnover in the heart (basal estimates are 9% per day [273]), 
previous studies of MMP and TIMP knockout mice have shown these to be cardio-
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protective genetic deletions [253]. Suppression of MMP and TIMP expression was 
alleviated following 4 weeks of PO in AdKO mice, corresponding with increased 
myocardial fibrosis. In WT mice, Col I and III, and MMP2 were upregulated following 
2 weeks of pressure overload, while at 4 weeks, gene expression of MMPs 8 and 9 were 
enhanced. Changes in MMP expression and activity following acute or chronic 
pressure overload has been noted previously [308], and is typically associated with 
increased differentiation of myofibroblasts, and the overall progression of cardiac 
remodelling.  
The presence of α-SMA positive cells (a strong indicator of myofibroblasts) in 
the myocardium is a common indicator of myocardial stress and decreased ventricular 
compliance [250], while localization of differentiated myofibroblasts to the peri-infarct 
area has been associated with decreased cardiac function following MI, as 
myfibroblasts secrete high levels of MMPs and collagen as part of the innate cardiac 
repair mechanism [272]. In this study we noted the presence of myofibroblasts in the 
sham AdKO myocardium which may account for the increased presence of small fibre 
fibrosis observed via SEM. Typically, immediate expansion of the ECM following PO 
and MI is associated with adaptive remodelling, contributing to the preservation of 
cardiac function. Here we observed that fibrosis following 4 weeks of MTAB was 
reduced in AdKO mice compared to WT mice suggesting a delay in ECM remodelling 
due to adiponectin deficiency. Accordingly, functional data comparing AdKO and WT 
mice show that POH and cardiac dysfunction are delayed in AdKO mice subjected to 
MTAB surgery (chapter 4: study 3). Taken together, we postulate that adiponectin 
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deficiency permits the presence of myofibroblasts in the normal myocardium, thereby 
inducing non-pathological small fibre cardiac fibrosis that confers short-term 
protection of cardiac function following the induction of pressure overload.  
To study adiponectin induced fibroblast activation, we treated isolated 
neonatal cardiac fibroblasts with the potent inducer of myocardial fibrosis 
angiotensin II (AngII). We found that adiponectin pre-treatment significantly 
inhibited AngII induced fibroblast to myofibroblast differentiation. Certainly, further 
study is needed to confirm that the presence myofibroblasts observed in the sham 
AdKO myocardium is directly due to adiponectin deficiency, however, we now propose 
that adiponectin deficiency permits AngII induced myofibroblast differentiation in the 
AdKO heart leading to small fibre fibrosis, observed via SEM, and protection against 
MTAB induced ECM expansion. Cross-talk between adiponectin and AngII signalling 
has been previously suggested as previous studies had shown that AngII could 
induced PARP-1 activation, which in turn downregulates adiponectin mRNA 
expression in cardiac fibroblasts, suggesting that adiponectin and AngII may share a 
ying-yang relationship in the heart. Clearly, the adiponectin-AngII balance could 
prove to be an important feature in the local production and actions of adiponectin 
and AngII in the remodelling heart, especially with respect to the development of 
fibrosis. 
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We had previously demonstrated regulation of matrix metalloproteinase 
activity in isolated neonatal cardiac fibroblasts by the metabolically potent globular 
form of adiponectin (gAd) [108], chapter 3:study 2. Interestingly, we noted that while 
gAd induced significant remodelling of the ECM produced in vitro through the 
upregulation of MMP activity, gAd treatment did not alter collagen gene expression 
or secretion [108]. In this study we show that recombinant full-length adiponectin, 
which contains a biologically relevant mixture of all three adiponectin isoforms, 
significantly induces collagen expression in vitro. An understanding of the ability of 
the different isoforms of adiponectin to mediate either MMP activity or collagen 
expression from cardiac fibroblasts may be an important factor in delineating 
adiponectin’s role in cardiac remodelling especially since circulating adiponectin 
levels are known to change with PO and correlate with different physiological 
outcomes in metabolism and heart disease [112].  
Circulating and myocardial transcript levels of adiponectin were reduced 
following surgery while there was a significant increase in myocardial adiponectin 
protein detected by western blot analysis, indicating the increased retention, and 
bioavailability of adiponectin within the fibrotic myocardium [160]. This may be an 
important mechanism serving to offset observed PO induced adiponectin resistance 
(i.e. downregulation of AdipoRs and APPL1). The importance of adiponectin 
accumulation and enhanced bioavailability at sites of cardiac injury [117, 135], as well 
as the putative liberation of the potent gAd through inflammatory cell derived 
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leukocyte elastase [80] adds to the complexity of local adiponectin action within the 
heart. Together, these changes strongly suggest a dynamically changing profile of 
adiponectin action in the remodelling heart. 
Early studies using AdKO mice demonstrated the detrimental effects of 
adiponectin deficiency on PO induced cardiac remodelling, including exacerbated 
cardiac hypertrophy and fibrosis, as well as accelerated functional decline [116, 157, 
158]. These studies are often cited as evidence of the cardioprotection of adiponectin 
in light of the emerging complex clinical association of adiponectin with various states 
of heart failure [133, 301, 302]. However, recent studies in AdKO mice following PO 
by Stanley instead demonstrate the permissive role of adiponectin in the pathogenesis 
of adverse remodelling events [161, 162]. The data presented in this chapter adds to 
accumulating evidence that adiponectin may play a detrimental role in the 
development of PO induced heart failure. While it remains clear from all studies that 
adiponectin plays an important role in the response of the heart to PO, the simple 
view of adiponectin as either cardioprotective or maladaptive must be refined with 
further detailed analysis of the complex pathogenesis of heart disease. 
 In conclusion, our studies suggest that adiponectin deficiency delays the 
progression of PO induced fibrosis. Small fibres in the AdKO myocardium that serve 
to support the heart against hemodynamic load may be a result of AngII-induced 
myofibroblast differentiation permitted by adiponectin deficiency. In WT mice, 
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however, ECM expansion following PO may serve to retain adiponectin within the 
myocardium to offset adiponectin resistance.   
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3.1 Abstract 
Defects in adiponectin action have been implicated in the development of 
cardiac dysfunction in obesity and diabetes. Cardiac fibroblasts play an important 
role in regulating extracellular matrix remodelling yet little is known regarding the 
direct effects of adiponectin on cardiac fibroblasts. In this study, we first 
demonstrated temporal relocalization of cellular APPL1 in response to adiponectin in 
primary cardiac fibroblasts and that siRNA-mediated knockdown of APPL1 
attenuated stimulation of AMPK by adiponectin. The cell surface content of MT1-
MMP and activation of MMP2 were induced by adiponectin and these responses were 
dependent on AMPK signalling. Enhanced MMP activity facilitated increased 
fibroblast migration in response to adiponectin which was also prevented by 
inhibition of AMPK, with no change in cell proliferation observed. Collagen and 
elastin immunofluorescence demonstrated reorganization of the extracellular matrix 
in accordance with increased MMP activity, whereas quantitative mRNA 
analysis,3H-proline incorporation and picrosirius red assays showed no change in 
intracellular or extracellular total collagen levels in response to adiponectin. In 
summary, these data are the first to report the adiponectin stimulated APPL1-AMPK 
signalling axis in cardiac fibroblasts and characterize MT1-MMP translocation, 
MMP2 activity and cell migration as functional outcomes. These effects may be of 
significance in heart failure associated with obesity and diabetes.  
 




The growing epidemic of obesity and diabetes has caused a disturbing and 
rapid increase in the incidence of heart disease [128, 309]. Extensive studies have 
indicated that altered circulating levels of adiponectin are associated with cardiac 
remodelling and dysfunction in obesity and diabetes [128, 148]. The majority of 
studies indicate a cardioprotective role of adiponectin which is mediated via 
regulation of multiple myocardial remodelling events [148, 310]. The metabolic, anti-
hypertrophic and anti-apoptotic effects of adiponectin are well established and 
adiponectin has also been shown to mediate anti-fibrotic effects [148, 303].   
The cardiac extracellular matrix (ECM) is a highly structured interstitial 
network of proteins composed mainly of collagens that surrounds the contractile 
cardiomyocytes. Remodelling of the ECM is widely accepted to have broad 
implications on cardiac function [250]. Fibrosis is commonly observed in various 
models of heart disease in rodents and in human failing hearts [311, 312]. Cardiac 
fibroblasts are the most prevalent cell type in the heart, and regulate ECM dynamics 
through the expression and regulation of collagens, matrix metalloproteinases 
(MMPs), and tissue inhibitors of MMPs (TIMPs) [249, 253]. Acute and chronic 
stressors such as myocardial infarction and hypertension have been shown to induce 
MMP expression and activity to degrade structural ECM proteins. After myocardial 
infarction, cardiac fibroblasts migrate to the damaged area to participate in repair 
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[304, 313]. This can initially aid contractile function but renewal of matrix with poorly 
structured collagen increases myocardial stiffness and contributes to dysfunction. A 
more detailed understanding of adiponectin's effects and mechanism of action on 
cardiac fibroblasts is needed.  
Many cardioprotective effects of adiponectin have been shown to be mediated 
via AMPK [314] and recent work in skeletal muscle, cardiomyocytes, endothelial cells 
and hepatocytes have shown APPL1, an adaptor protein containing an NH2-terminal 
BAR (Bin/Amphiphysin/Rvs) domain, a PH (pleckstrin homology) domain, a COOH-
terminal PTB (phosphotyrosine-binding) domain, and a leucine zipper motif, plays an 
essential role in activation of AMPK by adiponectin [54, 113, 315-319]. However, 
adiponectin stimulated APPL1-AMPK signalling in cardiac fibroblasts, and the 
functional consequences, have not yet been shown.  
In the present study, we used primary rat cardiac fibroblasts to examine the 
direct effects of adiponectin on MMP expression, localization and activities and cell 
migration. Changes in collagen isoform expression and extracelluar collagen content 
and structure were determined. We also investigated if adiponectin's effects were 
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3.3 Materials and Methods 
Materials  
Recombinant globular adiponectin was produced in-house as previously detailed by 
[121]. Dulbecco’s modified eagle’s medium (DMEM), trypsin, antibiotic/antimycotic 
and fetal bovine serum (FBS) were obtained from Gibco Laboratories (Life 
Technologies Inc., Burlington, ON, CA). All culture plates were BD Falcon™ brand 
and purchased from BD Biosciences (Mississauga, ON, CA). The MF20 antibody was 
a kind gift from Dr. J.C. McDermott (York University, Toronto, ON, CA) and von 
Willebrand factor antibody was purchased from Affinity Biologicals Inc. (Ancaster, 
ON, CA). Anti-phospho-AMPKα (Thr172), anti-AMPKα, anti-APPL1, anti-βactin 
primary antibodies and  horseradish peroxidase (HRP)-conjugated secondary 
antibodies were purchased from Cell Signalling Technology (New England Biolabs 
Ltd., Whitby, ON, CA). The anti-collagen antibody was purchased from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA, USA) and the anti-elastin antibody was obtained 
from Elastin Products Company, Inc. (Owenville, M), USA). Western Lightening Plus 
ECL was obtained from PerkinElmer (Woodbridge, ON, CA). TRIzol® Reagent and 
all siRNAs used in this study were purchased from Ambion Inc. (Life Technologies 
Inc.), Lipofectamine® 2000 Transfection Reagent was obtained from Invitrogen (Life 
Technologies Inc.), and Alexa Fluor® 488 goat anti-rabbit antibody was obtained from 
Molecular Probes (Life Technologies Inc.).  The FITC-labelled goat anti-mouse 
antibody was obtained from Jackson ImmunoResearch Laboratories, Inc. (West 
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Grove, PA, USA). The MT1-MMP (MMP-14) antibody was purchased from Acris 
Antibodies Inc. (Cedarlane Labs, Burlington, ON, Canada). VECTASHIELD® 
mounting medium with DAPI was obtained from Vector Laboratories (Burlington, 
ON, Canada). RNeasy MinElute Cleanup and RT2 First Strand kits were purchased 
from QIAGEN Inc. (Mississauga, ON, CA). 3H-proline and 3H-thymidine were 
purchased from Amersham Biosciences (GE Healthcare Lifesciences, Baie d’Urfe, QC, 
CA). Amicon Ultra-15 Centrifugal Filter Units and Compound C were obtained from 
EMD Millipore (Billerica, MA, USA). The Pierce BCA Protein Assay kit was 
purchased from Thermo Scientific (Fisher Canada, Nepean, ON, CA). The 
SIGMAFAST OPD kit was purchased from Sigma-Aldrich (Oakville, ON, CA). The 
custom PCR array for collagens was purchased from SABiosciences (QIAGEN Inc.).  
Isolation, Culture and Adiponectin Treatment of Neonatal Rat Cardiac Fibroblasts  
Neonatal cardiac fibroblasts (CFs) were isolated from 3 – 4 day old Wistar rats as 
previously described [121]. Briefly, excised hearts were digested with 0.15% trypsin 
for 1 hour at room temperature. Trypsin was then neutralized with DMEM containing 
10% FBS, and digested cells were centrifuged (10 min at 2000 rpm), resuspended in 
DMEM containing 10% FBS and 1% antibiotic/antimycotic and plated onto culture 
plates. Following incubation at 37 °C for 1 hour in a 5% CO2 atmosphere, 
cardiomyocytes remaining in suspension were removed, and attached fibroblasts were 
replenished with complete growth medium described above. Cardiac fibroblast purity 
was assessed through MF20 (cardiomyocyte) and von Willebrand factor (endothelial 
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cell) staining [121] which showed less than 1% staining for non-fibroblast cells. CFs 
were passaged twice, grown to 100% confluence (or as otherwise indicated below) and 
then starved with serum-free DMEM for at least 3 hours prior to treatment with 
recombinant globular adiponectin (1.0 µg/ml).  
Western Blot Analysis  
Cells lysis and protein sample preparation for Western blot was conducted according 
to methods detailed by [305]. Primary anti-phospho-AMPKα (Thr172), anti-AMPKα, 
anti-APPL1, and anti-β-actin antibodies were used at 1:1000 dilutions, and 
appropriate HRP-conjugated secondary antibodies were used at 1:10,000 dilutions.  
Proteins were detected by chemiluminescence, quantified by densitometry using 
Scion Image software (Scion Corp., Frederick, MD, USA) and then normalized to 
either β-actin or total AMPK protein levels as appropriate.  
siRNA Transfection of Cardiac Fibroblasts  
CFs were grown to   ̴30 – 50% confluence in 12-well plates, and then transfected for 
4-6 hours with 100 nM control or APPL1 siRNA using Lipofectamine® 2000 
Transfection Reagent according to the manufacturer’s instructions. The APPL1 
siRNA sequence is as follows: GCUUAGUUCUUGUCAUGCAtt. Adiponectin 
treatment was commenced 48 hours post-transfection and APPL1 knockdown 
efficiency was assessed by Western blot as detailed above (see Western Blot Analysis).  
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RNA Isolation and Quantitative Real-Time PCR  
Total RNA was isolated from cultured CFs using TRIzol® Reagent according to the 
manufacturer’s instructions, and purified using the RNeasy MinElute Cleanup Kit to 
attain an A260/A280 ratio between 1.9 and 2.0. First-strand cDNA, synthesized from 
1 μg RNA using the RT2 First Strand kit, was used in a custom PCR array comprising 
96well plates pre-coated with primers for collagens-I, -III and -IV. Quantitative real-
time PCR was conducted using a Chromo4™ Detection system (Bio-Rad Laboratories 
Canada Ltd., Mississauga, ON, CA) according to cycling conditions outlined by the 
PCR array manufacturer. Data were analysed using RT2 Profiler PCR Array Data 
Analysis software (Version 3.5; QIAGEN Inc.) and normalized to GAPDH mRNA 
expression.  
Wound Scratch Migration Assay  
Fibroblast migration in response to adiponectin treatment was assessed using the 
wound scratch assay. Briefly, a sterile 200 μL pipette tip was used to scratch a vertical 
line through CFs grown to confluence in 12-well plates. Scratched wells were then 
thoroughly washed with PBS to remove unattached cells, starved overnight in 
serumfree DMEM, and then pretreated for 1 hour with DMSO or 20 μM Compound C 
before adiponectin treatment. Following the indicated adiponectin treatment times, 
cells were fixed in 90% methanol for 30 min at -20oC, however  prior to fixation, 1 or 
2 unscratched wells were also freshly scratched with a sterile 200 μL pipette tip to 
serve as ‘fresh scratch’ controls. The cells were washed once more with PBS and then 
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mounted using VECTASHIELD® mounting medium with DAPI. Fluorescent images 
were obtained using an Olympus BX51 confocal microscope (Olympus, Seattle, WA, 
USA) with a 20 x objective, and fibroblast migration was assessed as the closure of 
the scratch wound in arbitrary length units using Inkscape software 
(www.inkscape.org).  
Detection of Cell Surface MT1-MMP  
Cell surface MT1-MMP was quantified in intact CFs using an MT1-MMP antibody, 
which recognizes an extracellular epitope, and the SIGMAFAST OPD kit as 
previously described [81]. Briefly, adiponectin-treated cells were washed with PBS 
and fixed on ice for 3 min with 3% paraformaldehyde (PFA). The cells were then 
washed and incubated for 10 min with 1% glycine to neutralize the PFA, blocked for 
30 min in 5% goat serum, incubated on ice for 1 hour with MT1-MMP antibody (1:500 
dilution in blocking buffer) and then incubated for 1 hour at 4oC with HRP-linked 
anti-mouse antibody (1:1000). Cells were then washed with PBS, incubated for 30 min 
at room temperature with OPD reagent (0.8mL/well), following which 200 μL of 3M 
HCl was added to stop the reaction. An absorbance reading was taken for 1 mL of 
each sample at 492nm using a spectrophotometer.   
MMP2 Activity By Gelatin Zymography  
Media was collected from CFs grown in 6-well plates and concentrated using Amicon 
Ultra-15 Centrifugal Filter Units following adiponectin treatment at indicated times. 
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The protein content of the resulting concentrated conditioned media was determined 
using the Pierce BCA Protein Assay kit, and then equal amounts of protein from 
media (25 μg) were resolved by SDS-PAGE on a 10% polyacrylamide gel containing 
0.3% gelatin. The gel was washed for 1 hour in a solution of 2.5% Triton X-100, briefly 
rinsed with deionized water, and then incubated for 18 hours at 37 °C in 1M Tris–
HCl (pH 7.6) containing 100mM CaCl2 to activate MMP gelatin degradation. MMP 
activity was stopped using a 10 min wash in 1M Tris–HCl (pH 7.6) containing 100mM 
EDTA. Gels were then fixed and stained in a solution containing 50% methanol, 10% 
acetic acid and 0.25% Coomassie Blue R-250. Areas of gelatin degradation, which 
were correlated with known molecular weights of MMP2 isoforms, indicated MMP 
activation. MMP2 activity was quantified by densitometric analysis of degraded areas 
using Scion Image software (Scion Corp.).  
Immunofluorescent Imaging of Endogenous APPL1 and MT1-MMP, and Secreted 
Collagen and Elastin   
CFs were seeded onto 25 mm coverslips. For APPL1 and MT1-MMP imaging, CFs 
were grown to   ̴30 - 50% confluence in DMEM containing 10% FBS before adiponectin 
treatment. For collagen imaging, CFs were initially grown as above for one day, and 
then cultured for 3 days in DMEM containing 10% goat serum prior to adiponectin 
treatment. For elastin imaging, CFs were cultured as described above for collagen 
imaging, however cells were grown in DMEM containing 10% FBS. Following 
adiponectin treatment at indicated times, cells cultured for APPL1, MT1-MMP and 
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collagen I imaging were gently washed with PBS, fixed with 3% PFA for 30 min at 
room temperature, and then incubated with 1% glycine for 10 min at room 
temperature to quench PFA. Alternatively, cells cultured for elastin imaging were 
fixed for 30 min with 90% methanol at -20oC. After fixation, the cells were then 
blocked at room temperature in either 5% goat serum for 1 h for APPL1 and MT1-
MMP imaging, 1% horse serum for 30 min for collagen imaging or 1% goat serum for 
30 min for elastin imaging, followed by incubation at room temperature with rabbit 
anti-APPL1 (1:1000 dilution in respective blocking buffer), mouse anti-MT1-MMP 
(1:200), rabbit anti-collagen I (1:100) or rabbit anti-elastin (1:100) antibody for 1 hour. 
Cells were then incubated at room temperature with AlexaFluor 488 goat anti-rabbit 
(1:1000) or FITC-labelled goat antimouse (1:1000) secondary antibody respectively for 
1 hour, followed by a final wash with PBS, and mounting on glass microscope slides 
using VECTASHIELD® mounting medium with DAPI. Immunofluorescent images 
were obtained using an Olympus BX51 confocal microscope (Olympus, Seattle, WA, 
USA) with 20x and 60x objectives.  
3H-Proline and 3H-Thymidine Incorporation Assays  
Pro-collagen synthesis and fibroblast proliferation was assessed by measurement of 
cellular 3H-proline and 3Hthymidine uptake respectively as previously outlined 
[320]. Briefly, CFs were treated with or without adiponectin in the presence of 3H-
proline or 3H-thymidine (1 μCi/mL final concentration) for the indicated times. At the 
end of each treatment period, cells were incubated for 30 min with ice-cold 5% 
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trichloroacetic acid (TCA) at 4°C. The resulting acid precipitate was then solubilized 
overnight in 0.5 ml of 0.5 N NaOH at 37°C and neutralized with 0.5 ml 0.5 N HCl per 
well. The radioactivity of each sample was measured in a liquid scintillation counter 
and corrected for total protein content using the Pierce BCA Protein Assay kit.  
Picrosirius Red Detection of Secreted Collagen  
CF conditioned media was collected and concentrated following adiponectin 
treatment, and subsequent protein content was determined as described above (see 
MMP2 Activity By Gelatin Zymography). Equal amounts of concentrated media (  ̴60 
μg) was then dried at 37oC in wells of a 96-well plate. To stain collagen, 0.1% 
picrosirius red solution was added to dried wells for 1 hour at room temperature. 
Wells were then washed with 10 mM HCl, and the stain was eluted with 0.1 M NaOH 
for 5 minutes. Eluate absorbance was read at 540nm using a spectrophotometer, and 
the collagen content of each eluate was quantified based on a collagen standard curve.  
Statistical analysis  
Data are expressed as mean values ± SEM (n), where n represents the number of 
experiments conducted. Student’s t tests were used to determine significant 
differences (P < 0.05) between groups. All statistical analyses were conducted using 
SigmaStat 3.5 Software (Systat Software Inc., San Jose, CA, USA). 
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3.4 Results 
Activation of AMPK by adiponectin was APPL1 dependent  
Immunofluorescent imaging of APPL1 localization in CFs revealed a diffuse 
cytosolic localization under unstimulated conditions (Fig. 3.1A). Adiponectin 
treatment induced an initial (10 and 15 min) redistribution of APPL1 to the cell 
membrane where it is likely to directly bind with adiponectin receptors. Changes in 
APPL1 were clearly time-dependent with nuclear and peri-nuclear localization of 
APPL1 evident after 30 min (Fig. 3.1A). We next used siRNA to knockdown APPL1 
expression (Fig. 3.1B, top) and showed that adiponectin stimulated AMPK 
phosphorylation was significantly inhibited after APPL1 knockdown (Fig. 3.1B&C). 
siRNA transfection achieved ~65% APPL1 knockdown as determined by Western blot 
(data not shown). Of note, we observed a slight increase in basal AMPK 
phosphorylation after APPL1 knockdown, with no changes in total AMPK expression 
(Fig. 3.1B).   
Adiponectin stimulated MT1-MMP translocation to the cell surface and MMP2 
activation, and these effects were mediated via AMPK  
To characterize the effects of adiponectin on MMPs in CFs, we first examined 
cell surface localization of MT1MMP. This was achieved by antibody-based detection 
of an exofacial epitope in intact cells and quantitative analysis of cell surface MT1-
MMP showed over 2-fold increased levels following adiponectin treatment (Fig. 
3.2A&B). This observation was supported by qualitative immunofluorescent data 
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(Fig. 3.2C). To examine mechanisms of this response, we first studied the 
consequences of reducing APPL1 expression using siRNA and demonstrated that the 
adiponectin response was significantly blunted (Fig. 3.2A). In addition, after 
pretreatment of cells with Compound C to inhibit AMPK the adiponectin-stimulated 
translocation of MT1-MMP to the cell surface was also significantly attenuated (Fig. 
3.2B). Zymographic analysis of CF conditioned media demonstrated an increase in 
MMP2 activation by adiponectin treatment, which was significantly attenuated by 
pretreatment with Compound C (Fig. 3.2C).   
Adiponectin induced cardiac fibroblast migration via AMPK signalling  
We performed the wound-scratch assay to measure the effects of adiponectin 
on CF migration. Adiponectin significantly increased CF migration after 40, 60 and 
120 min of treatment (Fig. 3.3A&B). Adiponectin had no significant effect on cell 
proliferation measured via 3H-thymidine incorporation (Fig. 3.3C). Compound C 
significantly attenuated adiponectin-stimulated CF migration (Fig. 3.3A&B). There 
was no significant difference in cell migration between DMSO only, Compound C only, 
or ‘fresh scratch’ wells (data not shown).  
Adiponectin does not alter collagen synthesis and secretion but induces collagen and 
elastin remodelling  
Under basal conditions, CFs secrete and assemble a collagen I matrix with a 
wispy and homogenous appearance (Fig. 3.4A). In keeping with the enhanced MMP 
activity, degradation of this collagen matrix was observed after 1 and 3 hours of 
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adiponectin treatment (Fig. 3.4A). Interestingly, a restored collagen matrix was 
observed 24 hours after adiponectin treatment. This newly formed matrix appeared 
more heterogeneous with larger collagen fibril aggregates, giving a thickened and 
patchy appearance (Fig. 3.4A). Examination of intracellular pro-collagen synthesis by 
3H-proline incorporation (Fig. 3.4B) and total secreted collagen in CF conditioned 
media measured by picrosirius red staining (Fig. 3.4C) showed no change in response 
to adiponectin treatment. Using quantitative PCR analysis we also found that 
expression of collagen-I, -III and -IV isoforms were not altered by adiponectin (Fig. 
3.4D). The CF elastin matrix also appeared to be similarly degraded upon adiponectin 
treatment (Fig. 3.4E).  
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Figure 3.1: Activation of AMPK by adiponectin is APPL1 dependent 
(A) Immunofluorescent images of APPL1 (green) in cardiac fibroblasts stimulated with 
adiponectin (1 μg/mL) for 10, 15 and 30 min. Cell nuclei were also stained with DAPI (blue). 
Representative images of n = 3 experiments are shown. Open arrows indicate membrane 
localization. Closed arrow indicates peri-nuclear localization. (B) APPL1 or non-specific 
control siRNA transfected cardiac fibroblasts were treated with adiponectin for 5, 10 and 15 
min, and immunoblotted for phospho-AMPK, total AMPK, and APPL1 to verify knockdown 
efficiency. Representative Western blots are shown from n = 3 experiments. (C) Phospho-
AMPK was quantified and normalized to total AMPK. Data represent mean values ± SEM 
from n = 3 experiments. *Significant difference (p < 0.05) from control. ^Significant 
difference (p < 0.05) from adiponectin treatment group at corresponding time point.  
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Figure 3.2: Adiponectin stimulates MT1-MMP translocation to the cell surface and MMP2 
activation via AMPK 
Cell surface MT1-MMP was examined by OPD assay in cardiac fibroblasts that were treated 
with adiponectin (1 μg/mL) at indicated time points and following (A) knockdown of APPL1 
using siRNA versus scrambled control or (B) 1 hour pre-treatment with either vehicle 
(DMSO) or 20 μM Compound C. Data represent mean values ± SEM from n = 3. (C) 
Representative immunofluorescent images from n = 3 experiments are shown of MT1-MMP 
(green) localization in adiponectin treated cardiac fibroblasts. Cell nuclei were also stained 
with DAPI (blue). Open arrow indicates MT1-MMP membrane localization. Top images 
were taken using a 60X objective, and bottom images were digitally enhanced 2X to achieve 
120X magnification. (D) MMP2 activation was analyzed by gelatin zymography in 
conditioned media collected from 1, 2 and 4 hours adiponectin treated fibroblasts that were 
pre-treated for 1 hour with either DMSO or 20 μM Compound C. A representative gel, 
indicating inactive ( ̴ 68 kDa) and active ( ̴ 62 kDa) MMP2 isoforms, is also shown in (C). 
MMP2 activity represents the MMP2 active/inactive ratio. Data represent mean values ± 
SEM from n = 3 experiments. *Significant difference (p < 0.05) from control. ^Significant 
difference (p < 0.05) from adiponectin treatment group at corresponding time point.  




Figure 3.3: Adiponectin induced cardiac fibroblast migration via AMPK signalling. 
(A) Cell migration was examined using the wound scratch assay in adiponectin treated (1 
μg/mL) cardiac fibroblasts following 1 hour pre-treatment with either DMSO or 20 μM 
Compound C. Cell nuclei were stained with DAPI and imaged using fluorescent microscopy 
under a 20x objective. Colours were digitally inversed so that cell nuclei are shown as black 
against a white background. Cell migration was quantified in (B) as the reduction of the 
wound width, as denoted by the solid lines in (A). Data represent mean values ± SEM from 
n = 3 experiments, using 7-10 images per group for quantification. (C) Fibroblast 
proliferation was assessed by 3H-thymidine incorporation following 6 or 24 hours 
adiponectin treatment. Data represent mean values ± SEM from n = 3 experiments. 
*Significant difference (p < 0.05) from untreated control. ^Significant difference (p < 0.05) 
from adiponectin treatment group at corresponding time point. 
 




Figure 3.4: Adiponectin does not alter collagen synthesis and secretion but induces collagen 
and elastin remodelling. 
(A) Immunofluorescent images of extracellular collagen I (green) secreted from cardiac 
fibroblasts at 20x and 60x magnification. Cells were treated with adiponectin (1 μg/mL) for 
1, 3 and 24 hours. Cell nuclei were also stained with DAPI (blue). Representative images 
from n = 3 experiments are shown. (B) Intracellular pro-collagen synthesis was assessed by 
3H-proline incorporation following adiponectin treatment for 6, 24, or 48 hours. Data 
represent mean values ± SEM from n = 3 experiments using 3 wells per group for 
quantification. (C) Total secreted collagen was measured in fibroblast conditioned media 
following adiponectin treatment for 6, 24 or 48 hours by picrosirius red staining. Data 
represented as mean arbitrary units ± SEM from n = 7 experiments. (D) Collagen-I, -III and 
-IV mRNA expression was examined in cardiac fibroblasts following 24 hours adiponectin 
treatment by quantitative real-time PCR. Transcript expression was normalized with 
GAPDH mRNA abundance. Data represent mean values ± SEM from n = 3. (E) 
Immunofluorescent images of extracellular elastin (green) secreted from cardiac fibroblasts 
at 60x magnification. Cells were treated with adiponectin for 3 days. Cell nuclei were also 
stained with DAPI (blue). Representative images from n = 3 experiments are shown.  
 




Figure 3.5: Schematic diagram representing the main mechanisms of adiponectin induced 
APPL1-AMPK signalling, MT1-MMP translocation, MMP2 activation , and cell migration 
The schematic figure depicts an integrative summary of the data presented in this 
manuscript. (1) adiponectin binding to its receptor, (2) binding of APPL1 to AdipoR and (3) 
subsequent activation of AMPK (4) MMP isoforms are translocated to the cell membrane 
(MT1MMP) or secreted (MMP2) and (5) the inactive MMP zymogen which is secreted can 
be activated by MT1-MMP on the cell surface and facilitate cell migration. Abbreviations 
shown are for globular adiponectin (gAd) and adiponectin receptor (AdipoR). 
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3.5 Discussion 
  In this study, we present evidence for a role of adiponectin-stimulated APPL1-
AMPK signalling in MMP activation and cell migration in cardiac fibroblasts. The 
precise role of adiponectin in heart failure is not fully established, however the 
majority of studies suggest that adiponectin mediates cardioprotective effects and 
that lack of adiponectin in obesity and diabetes leads to heart failure [148, 310]. This 
is strongly supported by studies in adiponectin knockout mice. For example, pressure 
overload or ischemia/reperfusion induced fibrosis was exaggerated in these mice 
lacking adiponectin [116, 321]. Furthermore, angiotensin-II induced fibrosis and 
MMP activity was exaggerated in Ad-KO mice and the enhanced fibrosis in 
adiponectin knockout mouse studies could be corrected by replenishment of 
adiponectin [116, 175, 176, 321]. However, little is known regarding direct effects of 
adiponectin on cardiac fibroblasts. The main function of cardiac fibroblasts is the 
maintenance of ECM homeostasis to maintain structural integrity and therefore 
retain optimal heart function [250, 254, 304, 313]. This involves the synthesis and 
secretion of structural proteins, such as collagen I which accounts for 80-85% of 
myocardial collagen expression, and MMPs which degrade structural proteins.   
In this study we first examined the effect of adiponectin on principal MMP 
isoforms. MT1-MMP is a membrane type MMP and is translocated to the cell surface 
by various stimuli [322, 323]. In this location, MT1-MMP can mediate proteolysis of 
matrix components but, perhaps most importantly, it is an important activator of 
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other MMP isoforms which are secreted from cells as inactive zymogens [324]. Indeed, 
cleavage of MMP2 to its active form can be mediated via MT1-MMP and the 
coordination of MT1MMP and MMP2 activities in various cell types plays an 
important role in cell migration [325, 326]. In keeping with these dogma we show here 
that in cardiac fibroblasts adiponectin increased cell surface MT1-MMP levels and 
also increased MMP2 activity in extracellular media. Furthermore, we observed that 
adiponectin could enhance cell migration via a mechanism that is likely to be at least 
partly dependent on MT1MMP and MMP2 mediated effects. Taken together, the 
ability of adiponectin to coordinate MT1-MMP and MMP2 activities is likely to 
contribute to the cardioprotective role of this hormone via promoting fibroblast 
migration to areas of damaged tissue and promoting degradation of existing matrix, 
established as an initially favourable response to cardiac injury [299, 304].   
Primary cardiac fibroblasts in culture form an extracellular matrix which can 
be visualized with appropriate imaging approaches. We used immunofluorescent 
detection to show collagen-I degradation occurred after treatment of cells with 
adiponectin. We also noted reassembly of the collagen matrix upon prolonged culture, 
yet the organization of this reformed matrix appeared more disorganized and fibrous 
in nature, which may be analogous to adverse cardiac remodelling [327, 328]. Since 
there was no change in total collagen synthesis or secreted collagen levels with or 
without adiponectin treatment, we conclude that degraded collagen is replaced by 
continuous basal secretion of collagen by cardiac fibroblasts as total MMP activity 
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subsides. Deficiencies in cardiac elastin have been reported to be involved in various 
forms of heart failure [299, 329] and overexpression of elastin by gene therapy 
prevented cardiac dilation [330]. In cardiac fibroblast cultures, we found that 
enhanced MMP activity in response to adiponectin correlated with elastin 
degradation although the functional significance of this response would require 
further investigation.  
We studied the mechanisms of adiponectin action in cardiac fibroblasts and 
have provided evidence for activation of APPL1-AMPK signalling which leads to the 
ECM related changes described above. The siRNA mediated reduction in APPL1 we 
achieved in our experiments was not complete, yet it was functionally significant. This 
may reflect the importance of the balance between APPL1 and APPL2 levels since 
these isoforms exhibit a yin-yang relationship [120] and the expression of APPL2 is 
likely to significantly override the remaining APPL1 expression. Many of 
adiponectin’s effects in various cell types have now been shown to be mediated via 
APPL1 with AMPK as a downstream target [113, 314, 316, 317, 319], yet this is the 
first demonstration of such a mechanism in cardiac fibroblasts. One previous study in 
fibroblasts showed that adiponectin induced the expression of interleukin-6 (IL-6) 
which involved ERK1/2, AMPK and p38 MAPK signalling but that this was not 
mediated via APPL1 [331]. Other adiponectin signalling targets such as p38 MAPK 
and ERK1/2 in regulation of MMPs and matrix components in cardiac fibroblasts have 
yet to be studied.  
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The effects of adiponectin described here may be mediated via endocrine 
responses to adipose-derived adiponectin [112]. The presence of a local adiponectin 
system within the heart has been proposed [88] and suggests that fibroblast or 
cardiomyocyte derived adiponectin may participate in the maintenance of the cardiac 
ECM and normal heart function through autocrine and paracrine actions [112]. The 
concept of the heart producing a range of cardiokines has recently become established 
[332] and the contribution of effects mediated by locally produced versus circulating 
adipopnectin on cardiac remodelling is worthy of further investigation.  
In summary, the data we have presented here establishes that adiponectin 
signals via APPL1-mediated activation of AMPK to mediate important changes in 
MMP isoform localization and activity. Subsequently, cell migration is enhanced and 
structural ECM components are degraded. Study of these events in cardiac fibroblasts 
further develops our understanding of the diverse functions of adiponectin in the 
heart and may enhance our appreciation of adiponectins role in heart failure.   
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CHAPTER 4: STUDY 3 
 
MYOCYTE ENHANCER FACTOR-2 BINDING IS ATTENUATED IN 
ADIPONECTIN DEFICIENCY FOLLOWING PRESSURE OVERLOAD, 
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4.1 Abstract 
Cardiomyocyte hypertrophy in response to pressure overload (POH) is associated with 
increased heart mass, activation of the myocyte enhancer factor-2 (MEF2) family, and 
initiation of the fetal gene program indicated by atrial natriuretic factor (ANF) 
upregulation. The anti-inflammatory, anti-diabetic adipokine adiponectin has been 
implicated as a regulator of POH induced cardiac remodelling although little is known 
of adiponectin activated MEF2 and ANF activity. In this study we characterize POH 
related MEF2 activity in wild-type (WT) and adiponectin knockout (AdKO) mice 
subjected transverse aortic banding (MTAB). Cardiac hypertrophy was initiated in 
WT mice 1 week following MTAB surgery. Accordingly, cardiomyocyte diameter, 
heart weight, ANF mRNA expression, and MEF2 binding activity were significantly 
increased by MTAB surgery in WT mice. Conversely, MTAB induced hypertrophic 
changes in Ad-KO mice appear 4 weeks following surgery.  ANF mRNA expression 
was not increased, and MEF2 binding activity was decreased in AdKO MTAB animals 
compared to sham. Furthermore, treatment of isolated cardiomyocytes with 
recombinant adiponectin significantly induced MEF2 and ANF reporter activity.  
Our data suggests adiponectin targeted MEF2 and ANF activity in the myocardium 
may regulate cardiac hypertrophy in response to pressure overload. 
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4.2 Introduction 
Hypertrophic changes to the myocardium in response to pressure overload 
(PO) are characterized by increased cardiomyocyte diameter, left ventricular (LV) 
posterior wall thickness, and overall heart weight. Pressure overload hypertrophy 
(POH) is also associated with activation of the fetal gene program, indicated by the 
upregulation of atrial natriuretic factor (ANF), as well as increased activity of the pro-
hyertrophic myocyte enhancer factor-2 (MEF2) family [218, 333].  
Numerous studies have identified the adipocyte derived adipokine adiponectin 
as a major player in cases of chronic heart failure [148], and recently a study using 
minimally invasive transverse aortic banding (MTAB) surgery to induce chronic 
pressure overload implicated adiponectin as playing a permissive role in the 
development of hypertrophy [162]. Indeed, although adiponectin is known to activate 
p38 signalling [129], a well characterized inducer of MEF2 activation [224], little is 
known about adiponectin activation of MEF2 activity in the heart with respect to 
POH. 
In this study we characterize the progression of cardiac hypertrophy in wild-
type (WT) and adiponectin knockout (AdKO) mice following MTAB surgery, and show 
differential MEF2 activation in overloaded wild-type and adiponectin deficient 
hearts. We also examine POH induced changes of atrogin-1 and MuRF-1, two well 
characterized anti-hypertrophic genes [334], and lastly look at adiponectin stimulated 
MEF2 and ANF activity in cardiomyocytes. 
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4.3 Materials & Methods 
Materials 
Recombinant full-length adiponectin was produced in-house as previously detailed by 
[121]. Dulbecco’s modified eagle’s medium (DMEM), trypsin, antibiotic/antimycotic 
and fetal bovine serum (FBS) were obtained from Gibco Laboratories (Life 
Technologies Inc., Burlington, ON, CA). All culture plates were BD Falcon™ brand 
and purchased from BD Biosciences (Mississauga, ON, CA). TRIzol® Reagent was 
purchased from Ambion Inc. and Wheat Germ Agglutin, Alexa Fluor 488 Conjugate 
was purchased from Molecular Probes (Life Technologies Inc.). Hematoxylin Gill No. 
2 stain and Eosin-Y stain were purchased from Sigma-Aldrich (Oakville, ON, CA). 
RNeasy MinElute Cleanup and RT2 First Strand kits were purchased from QIAGEN 
Inc. (Mississauga, ON, CA). LOOK silk black braided non-absorbable 6-0 USP sutures 
were purchased from Harvard Apparatus (Holliston, MA, USA), titanium ligation 
clips and microclip ligating appliers used for MTAB were purchased from Teleflex 
Medical (NC, USA).  
 
Experimental Animals.  
Wild-type C57BL/6 male mice were purchased from Charles River Laboratories 
(Montreal, QC, Canada). AdKO (C57BL/6 background) and MEF2 lacZ transgenic 
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(CD-1 background) mice were routinely bred and genotyped in-house. Compound 
transgenics were bred by crossing MEF2 lacZ mice with adiponectin homozygous null 
mice to subsequently create MEF2 lac Z/ Adipo -/- (MEF2 LacZ/AdKO).  Experimental 
animals were housed in a temperature controlled environment under 12h light- 12h 
dark conditions, and were fed ad-libitum. Animal facilities meet Canadian Council on 
Animal Care guidelines and all protocols used were approved by the York University 
Animal Care Committee.  
 
Aortic Banding Surgery.  
Under general anesthesia (i.p. xylazine: 0.15 mg/g; ketamine: 0.03 mg/g), hair from 
the chest was removed and the surgical area disinfected with betadine. A skin incision 
was made along the midline from the neck to the rib cage and the chest cavity was 
opened. The rib cage and thymus were retracted to expose the trasverse aorta. A 27g 
needle is used to calibrate a microclip applicator. A titanium microligation clip is 
applied between the origins of the innominate and left common carotid arteries, 
constricting the transverse aorta to the gauge of the needle. The rib cage, muscles, 
and skin are closed with a 6-0 USP non-absorbable silk suture. The animals are then 
administered s.c. 0.03 μg/mg Buprenorphine and allowed to recover on a heating pad 
until fully awake. Sham surgeries are performed as above except the microligation is 
not applied to the transverse aorta. All mice were monitored after the procedure for 
normal behaviour. 
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Echocardiography.  
All mice were subjected to transthoracic echocardiographic analysis to measure heart 
function 2 or 4 weeks following aortic banding or sham surgery. Cardiac function and 
heart morphology were evaluated using echocardiography (Vevo 2100, VisualSonics). 
The animals were sedated using 3% isoflurane and maintained with 1~2% isoflurane. 
The parasternal long axis view (B-mode, M-mode) was obtained and measurements 
of cardiac structure and function were determined as described previously [335]. The 
individuals performing echocardiographic analysis of heart function were blinded to 
surgical group and genotype. 
  
Tissue collection and histology.  
Following echocardiography, mice were weighed and euthanized using cervical 
dislocation. Hearts were excised and quickly perfused with 30mM KCl  to induce 
diastolic arrest. Hearts were then weighed and divided for further analysis. . Mid-
ventricular cross-sections of freshly dissected heart tissue were fixed in 10% formalin 
solution for 1 hour then stored in 70% ethanol at 4oC until further processing. Fixed 
heart tissues were dehydrated to xylene and embedded in pure paraffin wax blocks. 
Scanning electron microscopy. Freshly dissected heart tissue was fixed in 2% EM 
grade gluteraldehyde in 0.1M sodium cacodylate buffer pH 7.3 for 1 hour at room 
temperature, then stored in 0.1M sodium cacodylate buffer, pH 7.3, 0.2M sucrose until 
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further processing. Fixed samples were dehydrated in a graded ethanol series (30-
100%) then two steps of hexamethyldisilazane. Coverslips were then mounted, gold 
sputter coated (Hummer VI Au/Pd 40/60), and imaged using a Hitachi S-520 scanning 
electron microscope. Images were captured using a passive image capture system 
(Hitachi, Quartz PCI Version 6). 
 
Gene analysis.  
Tissue was frozen then crushed in liquid nitrogen and homogenized in TRIZOL. 
mRNA was extracted following manufacturer’s specifications then processed using 
the QIAGEN RNeasy clean up kit to attain high purity (260/280 > 1.9, 260/280 
between 1.8 to 2.0). Atrogin-1 (Forward: CTTTCAACAGACTGGACTTCTCGA; 
Reverse: CAGCTCCAACAGCCTTACTACGT), MuRF-1 (Forward: 
TGTCTGGAGGTCGTTTCCG; Reverse: TGCCGGTCCATGATCACTT), ANF 
(Forward: GGCTCCGAGGGCCAGCGAGCAGAGCCCCTCA; Reverse: 
CGTGCCCCGACCCACGCCAGCATGGGTCC), and GAPDH (Forward: 
TTGCCATCAACGACCCCTTC; Reverse: TTGTCATGGATGACCTTGGC) were 
analyzed through real-time PCR using the following cycling conditions: 95oC/15 min, 
followed by 35 cycles of [95oC/30 sec, 55oC/30 sec, 72oC/30 sec], then 72oC/10 min. Melt 
curve analysis was used to ensure primer specificity. Average ΔCt values were 
adjusted by GAPDH then used to calculate fold/sham ratio. 
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MEF2 binding activity.  
MEF2 activity was analyzed in vivo and in vitro as described previously [336].  
 
Statistics. 
Statistical analysis was performed using the Student’s t-test and two-way ANOVA 
followed by Tukey’s Multiple-Comparison Test. Data are expressed as mean ± SE 
where p ≥ 0.05 was considered statistically significant 
 
4.4 Results 
Four weeks of transverse aortic constriction led to an increase in apparent 
heart size and a significant increase in p38 phosphorylation in MTAB hearts when 
compared to sham hearts (Fig 4.1A). Similarly, heart weight to body weight ratio was 
significantly increased 1 week following MTAB (Fig 4.1B). Wheat germ agglutinin 
staining in paraffin embedded myocardial cross-sections indicated a significant 
increase in cardiomyocyte cross sectional area 3 days after MTAB (Fig 4.2A,B). Trans-
thoracic echocardiography 2 and 4 weeks following surgery to assess cardiac 
performance showed a small but non-significant increase in left ventricular end 
systolic diameter (LVESD) and left ventricular posterior wall thickness (LVPWD), 
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while there was no apparent change in left ventricular end diastolic diameter 
(LVEDD). Fractional shortening (FS) was significantly decreased in WT mice after 2 
and 4 weeks of PO (Fig 4.3). These functional changes were delayed in AdKO mice to 
4 weeks following MTAB surgery. 
Accordingly, in contrast to WT mice, AdKO mice do not display an increase in heart 
weight or cardiomyocyte cross sectional area 2 weeks after MTAB, but instead show 
a similar level of cardiac hypertrophy when compared to WT mice following 4 weeks 
of pressure overload (Fig 4.4A,B). Cardiomyocyte linearity was impaired in WT mice 
following MTAB (Fig 4.4C). 
To investigate the role of MEF2 binding following pressure overload, MEF2-lacZ mice 
were crossbred with WT and AdKO mice. MEF2 activity, shown through ex-vivo x-gal 
staining of heart crossections was increased in WT mice following MTAB surgery. 
MEF2 binding was noticeably absent in AdKO MTAB mice despite a slight increase 
in MEF2 binding in AdKO sham vs WT sham mice (Fig 4.5A). PCR analysis of mRNA 
levels in heart homogenates showed the significant upregulation of ANF in WT MTAB 
hearts (fold sham), while MuRF-1 mRNA was downregulated in both AdKO and WT 
animals, and Atrogin-1 was significantly decreased in AdKO mice while increased in 
WT mice.  ANF mRNA was significantly downregulated in AdKO animals after 4 
weeks of MTAB (Fig 4.5B, C). Adiponectin treatment was found to significantly 
increase MEF2 and ANF binding activity in isolated neonatal cardiomyocytes (Fig 
4.5D).  




Figure 4.1: MTAB increases heart weight and p38 phosphorylation. 
A) Representative whole heart images taken immediately following euthanization after 4 
weeks of sham or MTAB surgery. Below is representative western blot analysis of total and 
phosphorylated p38 following 4 weeks of sham or MTAB surgery. n = 4 to 6 mice per group. 
B) Total wet heart weight adjusted for body weight at time of euthanization (mg/g) 
quantified in mice euthanized 3 days, 1, 2, 3, and 4 weeks following sham or MTAB surgery. 
n = 4 to 6 mice per group ± SEM. * = p < 0.05. 
  





Figure 4.2: Cardiomyocyte cross-sectional area after MTAB. 
A) Cardiomyocyte cross-sectional area from WT mice 3 days, 1, 2, 3, or 4 weeks following 
MTAB surgery. n = 4 to 6 mice per group ± SEM. * = p < 0.05. B) Representative 
immunofluorescent wheat-germ aggluttin staining of myocardial histological cross-sections 
taken from WT mice following sham or MTAB surgery.  
 
  





Figure 4.3: Echocardiographic analysis of AdKO and WT mice. 
Echocardiographic analysis of cardiac structure (LVEDD: left ventricular end diastolic 
diameter; LVESD: left ventricular end systolic diameter) and cardiac function (FS: 
Fractional shortening; LVPWD: left ventricular posterior wall dimension) of AdKO and WT 
mice 2 or 4 weeks following sham or MTAB surgery. Values are average of n = 4 to 7 mice 
per group ± sem. * = p < 0.05 vs respective sham. 
 
 




Figure 4.4: Cardiac hypertrophy is delayed in adiponectin deficient mice. 
 (A) Longitudinal sections of LV stained with H&E. (B) Immunofluorescent wheat germ 
agglutin staining for cardiomyocyte membrane in LV cross-sections. 5 – 10 images of n = 4 
to 6 mice per group. Cardiac hypertrophy assessed through heart weight (HW) to tibial 
Length (TL) ratio (C), and LV posterior wall dimension (D) in sham or MTAB animals after 
2 and 4 weeks of PO. 





Figure 4.5: MEF2 activity is increased in WT mice following MTAB 
(A) Representative longitudinal or crossectional scans of the myocardium following β-gal 
staining, indicating areas of MEF2 activity. (B). Heat map of quantified ANF, atrogin-1, and 
MuRF-1 mRNA isolated 2 or 4 weeks following surgery. Data is represented as relative 
change in mRNA, associated with change in colour. Values were calculated as C(t), adjusted 
with GAPDH, fold sham over MTAB. (C) Relative MEF2 and ANF binding activity using 
MEF2-luciferase and ANF-luciferase reporter assays n ≥ 3. * = p ≤ 0.05 vs control. 
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4.5 Discussion 
Early MTAB studies using AdKO mice clearly demonstrated that adiponectin 
deficiency exacerbated cardiac fibrosis and hypertrophy in the progression of POH 
[116, 156]. However, recent studies have indicated that adiponectin may play a 
permissive role in cardiac hypertrophy, and that adiponectin deficient mice may be 
protected from PO [161, 162]. In the data presented here, we show that WT mice 
develop LVH faster than AdKO mice. We also show that MEF2 activity is upregulated 
in WT hearts following MTAB, but is also upregulated in AdKO sham animals. Lastly 
we demonstrate that adiponectin treatment induces MEF2 and ANF activity in 
cardiomyocytes. 
Our previous data indicated that adiponectin deficiency may delay the onset 
of cardiac fibrosis (see chapter 2: study 1). The data presented here suggests that 
cardiac hypertrophy in AdKO mice is similarly delayed following MTAB surgery. Of 
note, we may conclude that the surgical technique performed in the study was 
successful since WT mice subjected to MTAB surgery exhibited common features of 
cardiac hypertrophy: increased posterior wall thickness, cardiomyocyte hypertrophy, 
and increased heart weight.  Furthermore, the individuals performing 
echocardiographic analysis of heart function were blinded to surgical group and 
genotype as much as possible. The observed changes to cardiac performance in WT 
mice (decreased fractional shortening, increased LV ESD) were stable from 2 to 4 
weeks following surgery indicating mild PO and the lack of progressive decline. 
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Conversely, MTAB failed to induce functional change or hypertrophic remodelling in 
AdKO mice until 4 weeks after surgery indicating that, as was noted previously, the 
progression of remodelling following the induction of pressure overload is altered in 
the absence of adiponectin. 
Our data aligns with recent findings regarding the permissive role of 
adiponectin in the pathogenesis of POH. While the discrepancies between these 
studies and the first data published using this model may be explained by differences 
in mouse diet and the gut micro-biota, variation in knockout models from different in-
bred colonies, or simply subtle differences in animal facilities and surgical technique, 
we sought to elucidate the transcriptional activity targeted by adiponectin in POH as 
a means to understand the specific mechanisms targeted by adiponectin following 
MTAB.  
MEF2 is a family of transcription factors known to play a potent hypertrophic 
role in the pathogenesis of heart failure and is strongly associated with the fetal gene 
program (see section 1.4.2).We crossbred AdKO mice with MEF2 reporter mice and 
subjected them to MTAB surgery. MEF2 activity was significantly increased in 
hypertrophic WT hearts and downregulated in AdKO mice following MTAB surgery. 
Accordingly, we found that adiponectin significantly increased MEF2 and ANF 
activity in isolated neonatal rat cardiomyocytes. 
Taken together, these data implicate adiponectin as a mediator of 
hypertrophic changes to the myocardium following MTAB surgery through MEF2 and 
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ANF activation. It is important to note however that, while cardiac hypertrophy is a 
negative clinical indicator of heart disease, hypertrophic remodelling is in fact an 
adaptive mechanism upregulated in order to compensate the overloaded LV against 
increased systolic wall stress (see section 1.4.1). Indeed, our mice failed to show a 
progressive decline in cardiac function potentially indicating that while the AdKO 
mice experienced a delay in the onset of hypertrophy, WT cardiac function was 
maintained in the adaptive phase of remodelling. 
Indeed, O’Shea et al. showed that 6 weeks of PO induces cardiac hypertrophy 
in both AdKO and WT mice although the pattern of remodelling was different between 
the two strains. WT mice were shown to exhibit signs of dilated cardiomyopathy, 
while AdKO mice presented with the more protective concentric hypertrophic 
phenotype [162]. 
We also note that MEF2 activity was significantly increased in AdKO sham 
animals. This data correlates with our findings in chapter 2: study 1 that AdKO sham 
animals exhibit a subtle increase in small fibre fibrosis. However, we found no 
functional differences between sham AdKO and WT mice. From this we speculate 
upon the existence of a compensatory mechanism upregulated in AdKO mice linking 
fibrosis and MEF2 activity in the basal state that may confer protection against PO.  
From our data and those of other groups, it is clear that adiponectin is a cardio-
important adipokine, but the exact role of adiponectin in the progression of heart 
failure remains controversial. Here we have presented novel findings that adiponectin 
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can activate MEF2 and ANF, two common markers of the fetal gene program. 
Whether or not this plays a vital role in the actions of adiponectin in heart failure 
requires further study. 
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5.1 Abstract 
Clinical unloading of the left ventricle through either aortic valve replacement or 
implantation of a left ventricular assist device (LVAD) has revealed the regressive 
capacity of the hypertrophic heart to regain normal cardiac function. This has been 
mimicked in mouse aortic constriction models of pressure overload (PO) hypertrophy 
using debanding surgery to unload the LV, initiating the regression of cardiac 
remodelling. The importance of the extracellular matrix (ECM) and changes which 
occur upon PO induced compensatory LV remodelling is well understood, although 
the consequences of debanding on ECM structure and LV function remains to be 
elucidated. In this study, we used minimally invasive transverse aortic banding (AB) 
in C57BL/6 mice and performed temporal analysis of cardiac remodelling up to 4 
weeks and then 2 weeks after debanding. Echocardiography showed that PO-induced 
changes at 4 weeks were consistent with compensatory concentric hypertrophy 
(increased LV mass and LVPWD; normal EF and FS), and were reversed upon LV 
unloading. Speckle tracking analysis indicated a significant increase in LV 
endocardial radial strain in AB hearts which was restored to normal following 
debanding. Scanning electron microscopy revealed that thick collagenous fibres 
observed after 4 weeks of PO were lost following debanding. However, the ECM 
retained an expansive and disorganized network of thin fibres. Gene array analysis 
showed that AB and debanding induced opposing trends on mRNA expression of 
MMP, TIMP, and collagen isoforms. Taken together, our data show that LV unloading 
- 127 - 
 
leads to normalization of LV function, hypertrophy and, gross fibrosis. However, the 
structure of the debanded ECM may have implications concerning the heart’s 
response to future myocardial stress. 
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5.2 Introduction 
Pressure overload induces pathological long term remodelling of the left 
ventricle with changes in hypertrophy and fibrosis and a concomitant decline in 
cardiac function [337]. However, it is well known that an initial compensatory 
remodelling also occurs, which serves to preserve ventricular function. Beta-blockers, 
ACE inhibitors and angiotensin II receptor antagonists (ARBs) have been successful 
in delaying the progression to maladaptive remodelling. Congestive heart failure 
(CHF) patients have benefitted from aggressive surgical techniques such as valve 
replacement and left ventricular assist device (LVAD) implantation, both of which 
directly alleviate pressure overload (PO) of the left ventricle [233, 234]. Indeed, 
accumulating clinical and experimental evidence has demonstrated the restoration of 
cardiac function and regression of left ventricular remodelling following unloading of 
the left ventricle, a process now commonly termed reverse remodelling [235, 236]. 
Left ventricular overload in mouse models using aortic constriction leads to 
features commonly observed in compensatory concentric hypertrophy: left ventricular 
hypertrophy (LVH), and increased posterior wall thickness (LVPWD). LV unloading 
through removal of the constricting aortic band (debanding), results in reverse 
remodelling of the left ventricle, restoration of normal cardiac function [237-239], 
activation of a unique gene expression profile [240] and increased autophagic flux 
[242], as long as debanding is performed before the heart enters decompensated 
failure [241]. Debanding was also shown to differentially regulate the expression of 
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collagen isoforms in the heart [239, 247], but considering the global impact of cardiac 
fibrosis in altering ventricular geometry, inducing diastolic dysfunction, and 
disrupting electrical synchronicity [253, 283, 307], a clearer structural picture of the 
3-dimensional architecture of collagen networks in the debanded myocardium is 
needed.  
There is a strong association between obesity, heart failure, and circulating 
levels of the adiponkine adiponectin [148]. Recently, a study in CHF patients showed 
a significant decrease in adiponectin levels, and also in the principle adiponectin 
signalling target AMPK. Upon LVAD implantation, AMPK activation and 
adiponectin levels were restored [338]. 
In this study, we aimed to image the collagen extracellular matrix following 
unloading of the left ventricle, and compare LV strain between overloaded and 
debanded animals. We also characterized changes in cardiac adiponectin sensitivity 
before and after aortic debanding. Unloading of the LV undergoing compensatory 
remodelling resulted in the loss of myofibroblasts within the myocardium. This 
correlated with different trends of MMP, TIMP and Col expression between the 
banding and respective sham group. Thick fibre fibrosis and LV strain were also 
significantly attenuated following debanding. However, the morphology of the post-
banded ECM suggests incomplete collagen regression and a fibrous structure 
typically associated with poor clinical outcome. 
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5.3 Materials and Methods 
Materials 
Anti-phospho-AMPKα (Thr172), anti-AMPKα, anti-APPL1, anti-β-actin primary 
antibodies and  horseradish peroxidase (HRP)-conjugated secondary antibodies were 
purchased from Cell Signalling Technology (New England Biolabs Ltd., Whitby, ON, 
CA). Western Lightening Plus ECL was obtained from PerkinElmer (Woodbridge, 
ON, CA). TRIzol® Reagent was purchased from Ambion Inc. (Life Technologies Inc.), 
and Alexa Fluor® 488 goat anti-rabbit antibody was obtained from Molecular Probes 
(Life Technologies Inc.).  The FITC-labelled goat anti-mouse antibody was obtained 
from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA). 
VECTASHIELD® mounting medium with DAPI was obtained from Vector 
Laboratories (Burlington, ON, Canada).RNeasy MinElute Cleanup and RT2 First 
Strand kits were purchased from QIAGEN Inc. (Mississauga, ON, CA). 3H-proline was 
purchased from Amersham Biosciences (GE Healthcare Lifesciences, Baie d’Urfe, QC, 
CA). The Pierce BCA Protein Assay kit was purchased from Thermo Scientific (Fisher 
Canada, Nepean, ON, CA). The custom fibrosis PCR array was purchased from 
SABiosciences (QIAGEN Inc.).  
 
Experimental animals 
Male C57BL6 (WT) mice (Charles River Laboratories, St. Constant, QC), 6 – 8 weeks 
of age were randomly allocated to treatment groups. Animal facilities met the 
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guidelines of the Canadian Council on Animal Care, and the protocols were approved 
by the Animal Care Committee of York University. Animals were acclimated a 
minimum of 5 days to a standard housing environment: temperature and humidity-
controlled rooms (21±2oC,35-40%), with a daily 12:12h light-dark cycle (lights on at 
0700) with access to regular chow diet ad libitum. 
 
Minimally Invasive Transverse Aortic Banding and Debanding 
Under general anesthesia (IP Xylazine 0.15mg/g; Ketamine 0.03mg/g), the mouse is 
kept in a supine position and the fur on the ventral surface removed with a depilatory 
cream, and the surface sterilized with betadine. A medial cranio-caudal incision is 
made through the skin from the neck to the bottom of the rib cage, and the neck 
muscles, fat, and thyroid are retracted to expose the trachea down to the suprasternal 
notch. An incision is made through the suprasternal notch 2-3 mm down the rib cage. 
The transverse aorta is visualized under low magnification between the innominate 
and left common carotid arteries. A titanium micro-ligation clip is applied across the 
transverse aorta using banding calipers calibrated to the width of a 26g needle. The 
sham surgery is performed as outlined above without the placement of the ligation 
clip. Upon completion of the procedure, the rib cage and skin are closed with silk 
suture, and the mice injected with Buprenorphine (s.c. 0.05 mg/kg) and placed face 
down on a warming pad until they awake. 
The debanding procedure was performed as above but titanium band was removed in 
debanded animals and not removed in sham-debanded animals. 
- 132 - 
 
Tissue collection. 
Mice were weighed and euthanized using cervical dislocation. Hearts were excised 
and perfused briefly with KCl to arrest the heat in diastole. Hearts were then weighed 
and divided for further analysis.  
 
Scanning electron microscopy.  
Freshly dissected heart tissue was fixed in 2% EM grade gluteraldehyde in 0.1M 
sodium cacodylate buffer pH 7.3 for 1 hour at room temperature, then stored in 0.1M 
sodium cacodylate buffer, pH 7.3, 0.2M sucrose until further processing. Fixed 
samples were dehydrated in a graded ethanol series (30-100%) then two steps of 
hexamethyldisilazane. Dried samples were attached to coverslips were then mounted, 
gold sputter coated (Hummer VI Au/Pd 40/60), and imaged using a Hitachi S-520 
scanning electron microscope. Images were captured using a passive image capture 
system (Hitachi, Quartz PCI Version 6).  
 
Tissue histology.  
Mid-ventricular cross-sections were fixed in 10% formalin solution for 1 hour then 
stored in 70% ethanol at 4oC until further processing. Fixed heart tissues were 
dehydrated to xylene and embedded in pure paraffin wax blocks. 
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Western Blot Analysis 
Cell culture lysis and protein sample preparation was conducted according to methods 
detailed by [305]. Heart tissue homogenate preparation is detailed [306]. Primary 
anti-phospho-AMPKα (Thr172), anti-AMPKα, anti-APPL1, anti-AdipoR1, anti-
AdipoR2, and anti-β-actin antibodies were used at 1:1000 dilutions, and appropriate 
HRP-conjugated secondary antibodies were used at 1:10,000 dilutions. Proteins were 
detected by chemiluminescence, quantified by densitometry using Scion Image 
software (Scion Corp., Frederick, MD, USA) and then normalized to either β-actin or 
total AMPK protein levels as appropriate. 
 
RNA Isolation and Quantitative Real-Time PCR 
Total RNA was isolated from cultured CFs using TRIzol® Reagent according to the 
manufacturer’s instructions, and purified using the RNeasy MinElute Cleanup Kit to 
attain an A260/A280 ratio between 1.9 and 2.0. First-strand cDNA, synthesized from 1 
μg RNA using the RT2 First Strand kit, was used in a custom PCR array comprising 
96-well plates pre-coated with primers listed in table 1. Quantitative real-time PCR 
was conducted using a Chromo4™ Detection system (Bio-Rad Laboratories Canada 
Ltd., Mississauga, ON, CA) according to cycling conditions outlined by the PCR array 
manufacturer. Data were analysed using RT2 Profiler PCR Array Data Analysis 
software (Version 3.5; QIAGEN Inc.) and normalized to GAPDH mRNA expression. 
Adiponectin, AdipoR1, AdipoR2, APPL1, APPL2, GAPDH mRNA expression 
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(primers, Tm listed in table 2) were analyzed by quantitative real-time PCR using 
DyNAmo HS SYBR® Green qPCR kit (Finnzymes, Woburn, MA) with a Chromo4 
Detection system and the following cycling conditions: Hot start: 95 oC for 15 minutes; 
35 cycles of: 95 oC for 30 seconds, anneling temp (table 2) for 30 seconds, 72 oC for 30 
seconds; final extension: 72 oC for 10 minutes. 
 
Statistics 
Data are expressed as mean values ± SEM (n), where n represents the number of 
experiments conducted. Student’s t tests were used to determine significant 
differences (P < 0.05) between groups. All statistical analyses were conducted using 
SigmaStat 3.5 Software (Systat Software Inc., San Jose, CA, USA). 
 
5.4 Results 
Blood flow dynamics are impaired by AB and restored by debanding 
To validate the AB and debanding surgeries we studied blood flow dynamics 
of the transverse aorta as measured from the origin of the innominate artery using 
pulse-wave (Fig 5.1A top row) and colour Doppler (Fig 5.1A bottom row) 
echocardiography. Banding of the transverse aorta between the innominate and left 
carotid arteries (Fig 5.1A) significantly reduced aortic peak gradient (TAPG) and peak 
velocity (TAPV) by 40% and 20%, respectively, throughout 4 weeks of PO (Fig 
5.1B&C). TAPG and TAPV were restored 1 week following debanding surgery, and 
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resulted in significantly higher values compared to sham 2 weeks after debanding 
(Fig 5.1B&C). 
 
Reverse remodelling of compensatory hypertrophy is induced by aortic debanding 
Common characteristics of pressure overload induced cardiac hypertrophy 
(increased total heart weight (HW), left ventricular mass (LV mass) and left 
ventricular posterior wall thickness (LVPWd)), are indicators of progressive cardiac 
remodelling initiated as a compensatory response to maintain cardiac function. AB 
surgery significantly increased HW to body weight ratio after 4 weeks (Fig 5.2A), LV 
mass after 1 and 2 weeks (Fig 5.2B), and LVPWd after 2, 3 and 4 weeks (Fig 5.2C). 
Measures of cardiac function, including ejection fraction, fractional shortening and 
cardiac output remained unchanged after up to 4 weeks of PO, and followed by 1 or 2 
weeks of debanding (Table 4.1). Changes to HW, LVPWD, and LV mass were 
ameliorated following debanding surgery (Fig 5.2A,B&C).  
 
LV strain is increased by PO 
Speckle tracking analysis of segmental LV strain shows an increase in radial 
(Fig 5.3a), but not longitudinal (Fig 5.3b), strain following PO. This change was 
ameliorated by debanding surgery. Segemental radial strain analysis (time-to-peak) 
shows regionalized difference in mid- anterior vs posterior wall strain. After 4 weeks 
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of PO, there was a significant delay in time-to-peak radial strain in the anterior mid-
ventricular endocardial wall (121 ms) as compared to the posterior mid-ventricular 
endocardial wall (35 ms). This difference was reduced after debanding (43 ms and 73 
ms respectively) (Fig 5.3c). Sequential analysis of individual sham and AB mice shows 
an increase in radial strain rate between 3 and 4 weeks after MTAB surgery. Strain 
rate is attenuated following unbanding (Fig 5.3d).  
 
Structural and molecular analysis of cardiac fibrosis after AB and debanding 
Initial analysis of 3-dimensional collagen architecture by scanning electron 
microscopy demonstrated increased collagen deposition after 4 weeks of PO compared 
to sham and that this was greatly reduced in debanded animals (Fig 5.4a). However, 
using a cell maceration technique to remove non-fibrous myocardial tissue, the 
absence of thick fibres, and disorganization of thin fibres in the debanded cardiac 
ECM is apparent (Fig 5.4b). Molecular analysis of collagen, MMP and TIMP isoform 
mRNA expression revealed a distinct fibrotic profile between banded and debanded 
animals. Collagens 3a1 and 4a1, as well as TIMPs 2 and 3 were preferentially 
upregulated in MTAB animals, while MMPs 8, 9, and 13 were upregulated after 
debanding (Fig 5.5).  Collagen 4a1 levels decreased slightly after PO and were not 
altered by debanding, however MMPs 2, 8, 9, 13 and 14 were all reduced only after 
PO (Fig 5.5). The increased presence of α-smooth muscle actin (αSMA) positive cells, 
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indicative of myofibroblasts (white arrows), after PO suggests a phenotype of more 
myofibroblasts, a trend which was lost in debanded animals (Fig 5.6).  
 
Adiponectin sensitivity and pressure overload 
MTAB induced a slight reduction in AdipoR1 and APPL1 gene and protein 
expression, while AdipoR2 expression was significantly attenuated compared against 
the sham myocardium. There was no detectable difference in gene expression of the 
adiponectin receptors or APPL1 between debanded and sham-debanded mice. 
Western blot analysis showed a decrease in AdipoR2 and APPL1 protein in MTAB 
animals compared to sham animals, while no difference was noted between debanded 
and sham-debanded mice. AMPK and p38 phosphorylation was decreased in MTAB 
animals.   





Figure 5.1: Transverse Aorta Blood Flow Dynamics in Banded and Debanded Mice 
(A) Transthoracic echocardiographic imaging shows placement of transverse aortic band (*) 
between inomminate and subclavian arteries (top left) results in impaired blood flow as 
shown through colour Doppler imaging (lower left). Debanded transverse aorta displays no 
residual narrowing of vessel (top right), and normal blood flow (lower right). Representative 
images of n = 7 animals per group. Red colour indicates blood moving to top of image; Blue 
colour indicates blood moving to bottom of image. (B) Pulse-wave dopper quantification of 
transverse aorta peak velocity (TAPV) and transverse aorta peak gradient (TAPG) of sham 
(white), banded (black), and debanded (striped) animals. n ≥ 4 per group; * = p ≤ 0.05 vs 
Sham. # = p ≤ 0.05 vs band. 
  





Figure 5.2: MTAB induced pressure overload hypertrophy is attenuated following 
debanding 
(A) Gross wet heart weight of sham (white), banded (black), and debanded (striped) animals 
immediately following euthanization and brief cardiac perfusion with KCl. (B) Left 
ventricular posterior wall thickness (LVPWD) measured through long axis m-mode 
echocardiography in prebanded (grey), sham (white), banded (black), and debanded (striped) 
mice. (C) Corrected Left ventricular mass (LV Mass) measured through long axis m-mode 
echocardiography in sham (white), banded (black), and debanded (striped) mice. (D) 
Representative picrosirius red stained transverse sections of sham, banded, sham-
debanded, and debanded hearts. All quantification: n ≥ 4 per group; * = p ≤ 0.05. 
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Table 5.1: Echocardiographic assessment of cardiac function 
  2 Wk 4 Wk 1 Wk DB 2 Wk DB 
Parameter Surgery: Sham MTAB Sham MTAB Sham-Debanded Debanded Sham-Debanded Debanded 
Heart Rate BPM 457 +/- 39 434 +/- 17 425 +/- 12 447 +/- 11 429 +/- 23 453 +/- 9 452 +/- 13 434 +/- 8 
Diameter;s mm 2.99 +/- 0.05 2.93 +/- 0.15 3.06 +/- 0.2 2.93 +/- 0.1 2.91 +/- 0.18 2.91 +/- 0.19 3.14 +/- 0.15 3.04 +/- 0.23 
Diameter;d mm 4.21 +/- 0.02 4.04 +/- 0.13 4.23 +/- 0.17 4.07 +/- 0.09 4.28 +/- 0.1 4.18 +/- 0.15 4.33 +/- 0.09 4.26 +/- 0.18 
Volume;s uL 34.77 +/- 1.38 34.79 +/- 4.25 37.29 +/- 5.77 33.83 +/- 3.03 34 +/- 5.21 34.22 +/- 5.27 39.83 +/- 4.45 38.86 +/- 6.71 
Volume;d uL 78.91 +/- 1.06 73.08 +/- 5.35 80.38 +/- 7.5 73.58 +/- 3.82 82.68 +/- 4.75 78.77 +/- 6.51 84.71 +/- 4.16 82.93 +/- 8.18 
Stroke Volume uL 44.13 +/- 2.44 38.28 +/- 1.79 43.1 +/- 2.92 39.75 +/- 1.46 48.68 +/- 2.79 44.56 +/- 1.7 44.88 +/- 1.49 44.07 +/- 3.04 
Ejection Fraction % 55.96 +/- 2.36 54.21 +/- 2.68 54.11 +/- 3.52 54.67 +/- 1.85 59.98 +/- 4.34 58.35 +/- 3.3 53.68 +/- 3.16 55.64 +/- 4.34 
Fractional Shortening % 28.95 +/- 1.57 27.93 +/- 1.66 27.83 +/- 2.17 28.13 +/- 1.14 32.28 +/- 2.99 30.82 +/- 2.2 27.74 +/- 1.99 29.32 +/- 2.88 
Cardiac Output mL/min 20.09 +/- 0.75 16.5 +/- 0.88 18.3 +/- 0.96 17.76 +/- 0.83 20.77 +/- 1.29 20.15 +/- 0.61 20.3 +/- 0.95 18.96 +/- 1.17 
  





Figure 5.3: Left ventricular strain analysis 
(A) Average radial strain of whole left ventricle from long axis m-mode echocardiography in 
sham (white), banded (black), and debanded (striped) mice. (B) Average longitudinal strain 
of whole left ventricle from long axis m-mode echocardiography in sham (white), banded 
(black), and debanded (striped) mice. (C) Time-to-peak analysis (longitudinal strain) from 
long axis m-mode echocardiography from mouse 10 after 4 weeks of banding (above), and 2 
weeks following debanding (below). Increased time-to-peak is represented as heat map. 
Anterior wall is towards top of image, posterior wall is towards bottom of image. (D) Average 
radial strain rate of whole left ventricle from long axis m-mode echocardiography from 
individual mice (mouse ID indicated in brackets) for study duration. 
 
  




Figure 5.4: Debanding induces reverse remodelling of the ECM 
(A) Representative scanning electron micrographs of ventricle samples obtained from 4 wk 
sham, 4 wk MTAB and 2 wk debanded animals. Thick collagen fibres may be seen in 
abundance in the MTAB images. (B) Representative scanning electron micrographs of 
ventricle samples obtained from 4 wk sham, 4 wk MTAB and 2 wk debanded animals. Non-
fibrous tissue was digested and washed out of samples after fixation as described in 
materials and methods section. Thick collagen fibres may be seen in abundance in MTAB 
images. Thin fibres appear more numerous and disorganized in Debanded images compared 
against Sham. 
  





Figure 5.5: Expression of fibrosis markers 
PCR array analysis of Collagen, TIMP, and MMP mRNA isolated from Sham, MTAB, Sham-
Debanded, and Debanded mice. Each axis corresponds to fold-change of header gene 
compared to respective sham. MTAB values (solid line) represented as fold C(t) vs. sham; 
Debanding values (green) represented as fold C(t) vs. sham-debanding (red). 
Downregulation shown as values < 1.0. n ≥ 4 per group. 
  






Figure 5.6: Myofibroblasts expression is lost following debanding 
Representative immunofluorescent images of transverse ventricular sections obtained from 
4 wk MTAB, 2 wk Sham-Debanded, and 2 wk debanded animals. Increased α-smooth muscle 
actin (αSMA) staining can be seen in MTAB and Sham-Debanded images. Little αSMA 
staining is seen in Debanded images. 
  





Figure 5.7: Adiponectin signalling 
Middle graphs: Quantitative PCR analysis of AdipoR1, AdipoR2, and APPL1 are shown as 
fold MTAB over Sham (black bars), or fold Deband over Sham-Deband (striped bars). n ≥ 4. 
* = p ≤ 0.05 vs sham. # = p ≤ 0.05 vs sham-deband. Western blot analysis of AdipoR1, 
AdipoR2, APPL1, phospho-p38, and phospho-AMPK with relevant loading control shown 
below. 
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5.4 Discussion 
Cardiac remodelling was classically viewed as a linear progression of 
geometric changes to the left ventricle concomitant with the development of fibrosis 
following a myocardial infarction, ultimately ending in heart failure. In fact, there is 
now accumulating evidence with respect to non-ischemic heart disease that the 
remodelled heart may undergo a reversal of maladaptive changes resulting in 
normalized cardiac function. Here we have presented evidence indicating that 
features of reverse remodelling extend to the structure of the extracellular matrix, 
highlighting the dynamic capabilities of the myocardium in actively regulating pro- 
and anti-fibrotic pathways to define the myocyte support structure. 
After 4 weeks of banding, blood flow dynamics of the transverse aorta were 
significantly impaired while LV mass and LVPWD were increased without changes 
to EF or FS. These data are consistent with PO induced compensatory cardiac 
remodelling involving concentric hypertrophy. In this background, debanding 
resulted in supra-normal blood flow across the transverse aorta and initiated 
regression of hypertrophic changes of the left ventricle. The decoupling of aortic blood 
flow and LV geometry may represent a transient phenomenon as myocyte contractile 
force exceeds hemodynamic load, implying a pressure ‘underload’ condition in which 
the contractile capacity of the left ventricle exceeds its pressure and volumetric 
demands. The maintenance of cardiac function through both overload and underload 
highlights the dynamic, compensatory abilities of the heart, but also masks the 
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underlying changes to cardiac structure, especially with respect to the extracellular 
matrix, which may have long term consequences to cardiac function. 
The initiation of cardiac fibrosis in PO serves a different function from the 
fibrotic response in MI. The increased deposition of collagen in a heart undergoing 
compensatory concentric hypertrophy establishes a stress-tolerant collagen scaffold 
to enhance systolic force generation, prevent diastolic over filling, and protect against 
myocyte slippage. As a result, the expanded ECM serves in a highly supportive role 
in PO stress, a distinct contrast to the necessarily final, reparative role an infarct scar 
plays in MI to replace lost myocytes and maintain LV structural integrity [250, 307].  
Our previous temporal analysis of MTAB induced fibrosis using scanning electron 
microscopy (chapter 2) showed the increased presence of ECM small fibres after 1 
week, followed by the appearance of thick, disorganized fibres after 4 weeks of 
pressure overload, characteristic of established models of cardiac fibrosis. We found 
the upregulation of pro-fibrotic processes following MTAB was a sharp contrast to the 
lesser degree of fibrosis associated with LV unloading, implying the activation of anti-
fibrotic pathways following debanding and may be a reflection of increased MMP gene 
expression. A finer analysis of the collagen ECM structure between our surgical 
groups using a cell-maceration technique to remove all non-fibrous material reveals 
a collagen network following debanding lacking the thick collagen strands commonly 
associated with cardiac fibrosis, but instead containing more (in apparent number) 
highly disorganized thin collagen fibres than the normal myocardium. There may be 
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negative electrophysiological consequences to this pattern of enhanced fibrosis as 
exacerbated cardiac fibrosis has been shown to disrupt cardiomyocyte electrical 
coupling, leaving the myocardium vulnerable to impaired signalling (e.g. 
arrhythmias) [283]. The pattern of expanded fibrosis in debanded mice correlates with 
previous findings in patients following LVAD implantation [339], and increased 
fibrosis in non-ischemic cardiac disease (e.g. aortic stenosis) is associated with 
increased risk of death due to cardiac failure [202, 244, 245].  
Aortic debanding has been associated with an increase in LC3-II, an indicator 
of autophagic flux [242]. Since hypertrophy of individual cardiomyocytes plays a 
principle role in the hypertrophic response to pressure overload, correlating changes 
in autophagy and atrophy with changes in overall cardiomyocyte cross-sectional area 
in our model of banding and debanding is a necessary and pending addition to this 
study. 
The association of adiponectin, the metabolically active adipokine, with 
various stages of heart disease is now well established [148] although the direct 
relationship between circulating adiponectin levels and prospective patient outcome 
remain elusive [38]. Indeed, the picture of a local adiponectin system, regulated 
independently from adipocyte derived adiponectin, is emerging as expression of 
adiponectin from cardiomyocytes has been shown both in vitro [85, 340, 341] and in 
congestive heart failure patients [88], and previously we demonstrated adiponectin 
mediated regulation of the ECM through stimulation of cardiac fibroblasts [108]. 
- 149 - 
 
However, when considering adiponectin as a therapeutic for heart failure, recent 
evidence that adiponectin sensitivity may be impaired by Angiotensin II signalling 
[182], the status of adiponectin sensitivity in non-ischemic cardiomyopathies needs to 
be addressed. Clinically, adiponectin sensitivity was recovered in patients with 
advanced heart failure following LVAD implantation [338]. Our data shows the 
downregulation of the adiponectin receptors AdipoR1 and AdipoR2, as well as the 
intracellular binding protein APPL1 following MTAB surgery, which may indicate the 
desensitization of the myocardium to adiponectin stimulation, correlating with the 
depressed activation of the well known adiponectin targets AMPK and p38. There 
was no detectable change in adiponectin sensitivity between sham-debanded and 
deband animals. The issue of adiponectin sensitivity within the overloaded 
myocardium takes on greater importance considering the continued and expanded 
use of pioglitazone and rosiglitazone, PPARγ agonists, in heart failure patients. 
Indeed, cardiomyopathic adiponectin resistance must be appreciated as a potential 
factor limiting adiponectin’s therapeutic efficacy. 
Although we and others have demonstrated the efficacy in unloading the left 
ventricle through debanding surgery for the study of reverse remodelling, other novel 
methods have yielded similar findings. Heterotopic transplantation was shown to 
achieve atrophic remodelling of the rat heart [342], while the injection of 
mesenchymal stem cells was shown to significantly improve hemodynamic 
performance, reverse LV remodelling, and improve exercise tolerance following aortic 
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banding [343], while increasing EF and capillary density in a model of doxorubicin-
induced heart failure [344].  
The data presented here highlights the ability of the heart to adapt to a prolonged, 
transient increase in LV pressure. However, while cardiac function is maintained 
throughout this phase of adaptive remodelling, non-symptomatic adverse remodelling 
of the collagen ECM may have a largely influence the structure of the ECM following 
unloading. The increased fibrosis noted following LV unloading may seriously impact 
future risk of cardiovascular mortality. This suggests that more attention should be 
paid to the mechanisms governing fibrosis. Therapeutics designed to limit non-
pathological fibrosis may hold long term benefits to individuals at high risk of 
developing heart disease.  
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CHAPTER 6: CONCLUSION 
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6.1 Summary of research 
The rise of the obesity and diabetes epidemics has caused an increase in 
worldwide cardiovascular risk [128, 309]. As a result, focus has been placed on finding 
factors linking these diseases. Adiponectin is one of the major secreted factors from 
adipose tissue, and exists in circulation at a relatively high concentration [39-41]. 
Numerous studies have demonstrated a negative relationship between circulating 
adiponectin levels and diseases such as obesity and T2D [42-44]. However, the data 
linking circulating adiponectin and various stages of heart disease are less clear, and 
indeed, there is much controversy as to the predictive value of circulating adiponectin 
levels on heart failure outcomes [38, 133]. Similarly, there is some conflicting data 
regarding the role that adiponectin plays in pressure overload models of heart disease 
[116, 156, 161, 162].  
Animal studies have suggested adiponectin influences fibrosis in models of 
heart failure [116, 118]. Adiponectin regulation of cardiomyocyte metabolism has 
been well characterized [112], but less is known about adiponectin mediated 
regulation of the extracellular matrix. For the studies presented here, I chose to focus 
on the regulation of the extracellular matrix by adiponectin in vivo, and adiponectin 
signalling mechanisms regulating effects in isolated cardiac fibroblasts.  
I first characterized the pattern of progressive fibrosis in the heart following the 
induction of pressure overload by transverse aortic banding surgery in wild-type mice. 
Collagen accumulation in the myocardium was characterized by an early increase in 
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small fibre collagens, followed by the appearance of thick, disorganized collagen 
fibres. At this time there was also an increased presence of hypersecretory 
myofibroblast cells in the heart, as well as an overall increase in heart size. 
Comparing the pattern of remodelling in wild-type to that in adiponectin deficient 
mice, I noted the delayed onset of fibrosis in the latter group. This correlated with a 
delay in cardiac dysfunction. From this study it was clear that the progression of 
fibrosis in heart disease is influenced by the presence or absence of adiponectin. I then 
sought to determine which adiponectin stimulated signalling pathways mediated 
changes in extracellular matrix components in cardiac fibroblasts, the cell type 
primarily responsible for mediating fibrosis in the heart. 
I used primary cardiac fibroblasts and found that adiponectin treatment 
activated the APPL1-AMPK signalling pathway, leading to increased cell surface 
localization of the membrane-bound ECM degrading enzyme MT1-MMP [174, 291]. 
An adiponectin-stimulated AMPK-dependent signalling mechanism also significantly 
increased fibroblast migration and activation of MMP2, another important regulator 
of the ECM that is closely associated with cardiac fibrosis. I theorized that MT1-MMP 
and MMP2 activation would regulate the ECM assembled by fibroblasts in culture. 
Accordingly, I found acute adiponectin stimulation resulted in a degraded collagen 
and elastin ECM in culture. Interestingly, the matrix was subsequently reassembled 
in a disorganized pattern, similar to the patterns noted in the first in vivo study. 
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Knockdown of APPL1 in fibroblasts inhibited adiponectin stimulated AMPK 
activation and MT1-MMP localization. To our knowledge, this study presents the first 
documented evidence that the intracellular AdipoR binding protein APPL1 can 
mediate remodelling of the extracellular matrix. The in vitro studies also firmly 
established that adiponectin action on fibroblasts is a potentially important 
mechanism in the progression of heart failure. 
Previous in vivo and in vitro data [85, 116], as well as my in vivo studies, have 
suggested that adiponectin may regulate cardiac hypertrophy in PO, but the 
transcriptional mechanisms involved were still unclear. Through collaboration with 
the McDermott lab, WT or AdKO were crossbred with transgenic MEF2-lacZ reporter 
mice, and then subjected to PO. We found that MEF2 activity was upregulated in WT 
mice following PO, but this trend was absent in AdKO mice. Accordingly, adiponectin 
stimulation increased MEF2 expression, as well as that of ANF, a MEF2 downstream 
target and key indicator of the pro-hypertrophic fetal gene program. This study 
provides the first evidence that adiponectin directly targets the pro-hypertrophic 
transcription factor MEF2, and stimulates the fetal-gene program through ANF 
upregulation. 
In 2012 a clinical study in heart failure patients suggested the existence of 
adiponectin insensitivity in the heart which could be reversed by unloading of the left 
ventricle [338]. In my final animal study, I had three goals: a) to establish a surgical 
model of LV unloading in our lab; b) to evaluate markers of adiponectin signalling 
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before and after LV overload; c) to image the extracellular matrix before and after 
unloading using the scanning electron microscope. Similar to the initial in vivo study, 
MTAB induced the accumulation of thick collagen fibres in the myocardium. These 
fibres were absent following unloading and replaced by disorganized thin fibres. The 
data regarding adiponectin sensitivity in the myocardium was not very conclusive and 
requires follow-up studies, although LV unloading significantly decreased LV wall 
strain and regressed LV hypertrophy. 
 
6.3 Future Experiments 
Work on chapters 1 and 3 is finishing. The final manuscripts are being edited 
for submission in May 2014. 
Future work will continue to characterize adiponectin signalling in cardiac 
fibroblasts. Other studies have indicated the role of p38-MAPK and ERK in 
adiponectin stimulated signalling in cardiac fibroblasts [331]. Using 
pharmacoloogical inhibitors and siRNA-mediated knockdown, the importance of 
these signalling molecules in adiponectin mediated ECM remodelling will be 
established. Furthermore, a clearer understanding of the functional differences 
between AdipoR1 and AdipoR2 in cardiac fibroblasts is necessary, as well as a 
characterization of the endogenous APPL1 inhibitor, APPL2 [120]. 
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Through related honours thesis projects that I supervised, we have 
preliminary data showing the upregulation of adiponectin transcription from 
cardiomyocytes and cardiac fibroblasts by the TZD rosiglitazone. Furthermore, we 
found that AngII is able to attenuate this effect, confirming previous findings that 
AngII could downregulate adiponectin expression via PARP-1 [185, 186]. Conversely, 
we have data indicating that adiponectin pre-treatment can inhibit AngII induced 
fibroblast to myofibroblast differentiation in vitro. In order to establish if 
adiponectin’s effects in this system are through a general inhibition of cell 
differentiation, or though targeted disruption of AngII signalling, we will follow up by 
using another potent inducer of myofibroblast differentiation: TGFbeta. The relative 
status of adiponectin sensitivity between cardiac fibroblasts and myofibroblasts is 
unknown. We will conclude this study by examining the expression of various 
components of the adiponectin signalling pathway (i.e. AdipoR1, AdipoR2, APPL1, 
APPL2), and compare adiponectin stimulated AMPK and p38-MAPK phosphorylation 
in cardiac fibroblasts and myofibroblasts. 
As highlighted in my introduction, the yin-yang relationship between 
adiponectin and AngII in the heart may prove to be a very important balance that 
needs to be considered in heart disease modes and in the development of therapeutics. 
Sample analysis for the reverse remodelling manuscript (chapter 4) is almost 
complete. However, the role of autophagy in the process of reverse remodelling 
following unloading of the LV has been suggested [242]. We will analyze TEM samples 
- 157 - 
 
and tissue homogenates generated from our debanding experiments to establish the 
presence of autophagy and mitophagy as part of our reverse remodelling model. 
Furthermore, we will expand this study in two ways: 1) study the changes to the ECM 
following debanding in mice exhibiting signs of decompensated heart failure (EF < 




Collectively, my studies show that adiponectin is an important player in the 
response of the heart to pressure overload, especially as a regulator of the ECM. My 
in vivo studies show that cardiac fibrosis and hypertrophy are delayed following 
MTAB surgery by adiponectin deficiency, and I propose that this is conferred through 
a fibrosis-dependent cardioprotective mechanism. Furthermore, through establishing 
the APPL1-AMPK signalling axis in cardiac fibroblasts, and identification of MEF2-
ANF targeting in cardiomyocytes, my work offers an expanded understanding of 
adiponectin signalling in the heart. Lastly, I show that ECM expansion in PO induced 
compensatory, non-pathological hypertrophy is incompletely resolved following LV 
unloading. This finding may have serious implications in the long term prognosis of 
hypertensive patients with respect to fibrosis induced diastolic dysfunction and 
progressive heart failure.  
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Along with our upcoming exciting data sets, we hope to provide significant 
insight into the actions of adiponectin in cardiac remodelling, as well as to introduce 
new potential targets in the development of therapeutics for heart disease.  
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